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INTRODUCTION 
The treatment of acute ST elevation myocardial infarction (STEMI) has greatly improved in 
the last three decades, especially after the introduction of primary percutaneous coronary 
intervention (PCI). However, primary PCI is available in selected centres only, thus 
necessitating transportation of the STEMI patient. Improvement in the logistics of care for 
these patients is associated with significant improvement of patient outcome. Both the 
American Heart Association (AHA) and the European Society of Cardiology (ESC) STEMI 
guidelines recommend pre-hospital infarct diagnosis as a class I recommendation [w1-w2]. 
Despite this, the large majority of STEMI patients are only diagnosed after arrival in the 
hospital [1]. Therefore, great care should be taken in the initial diagnosis, risk assessment 
and triage, subsequent transfer and the distance of transportation as well as pre- and in-
hospital time delays in these patients. 
 
PRE-HOSPITAL INFARCT DIAGNOSIS AND TYPE OF TRANSFER 
STEMI patients can be diagnosed in the pre-hospital phase in two ways. The first option is 
diagnosis in the ambulance via an emergency medical services (EMS) call (118 or 911) by the 
patient or by a general practitioner. The second option is diagnosis at a referral non-PCI 
centre after self-referral of the patient or when no pre-hospital electrocardiogram (ECG) is 
performed by EMS in the ambulance. Pre-hospital diagnosis in the ambulance gives the best 
outcomes for STEMI patients, since pre-hospital treatment can be started directly in the 
ambulance after diagnosis and triage [2-3]. Subsequently, these patients are directly 
transferred in an ambulance from the pick-up place to the nearest PCI centre with 24/7 
service, bypassing the emergency departments of the nearby referral non-PCI centres. The 
second option, diagnosis at a non-PCI centre, also occurs often, especially in rural areas. 
These patients are transported to a PCI centre, following diagnosis and triage of STEMI, 
preferably at the emergency department. STEMI patients can also be diagnosed in the PCI 
centre after self-referral, however, no pre-hospital triage, diagnosis and treatment is 
performed in these patients (Figure 1). Whether telemedicine can further improve pre-
hospital diagnosis in STEMI remains to be evaluated. A previous study showed a slightly 
higher incidence of false positive infarct diagnoses with ambulance or field triage (5% vs. 
1%), which can be overcome by electronic transfer of the ECG to the PCI centre. However, 
this is often associated with extra time delay [4]. 
 
ORGANISATION OF NETWORKS 
Since the angiographic and clinical outcome of STEMI patients is dependent on the type of 
pre-hospital diagnosis and type of transfer, more effort should be applied in improving the 
organisational issues in the pre-hospital phase. First of all, every region should be organised 
according to local practice, since there is no ‘one size fits all’ solution. The 
policymakers/(local) government play a pivotal role in order to optimise the system, that is, 
to ban the restriction that EMS is only used for inter-hospital transfer, or that ambulances are 
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not allowed to bypass non-PCI centres. Second, it is important to make patients and general 
practitioners aware of the fact that pre-hospital diagnosis with ambulance transport has better 
outcomes for STEMI patients than referring via a referral non-PCI centre, referring via general 
practitioners or self-referring. Third, use of pre-hospital ECG equipment with a computerised 
algorithm or electronic transmission of an ECG to a PCI centre can be helpful to achieve a 
faster initial diagnosis, and suggests a trend for a lower risk of mortality [1]. Fourth, diagnosis 
of STEMI can be performed by highly trained paramedics using ECG equipment with a 
computerised algorithm or teletransmission of the ECG. 
 
 
Figure 1. Pre-hospital management of ST elevation myocardial infarction (STEMI) patients.  
EMS, emergency medical services; PCI, percutaneous coronary intervention.  
Thick black lines: preferred pathway; black narrow lines; to be avoided. 
 
PRE-HOSPITAL RISK ASSESSMENT AND TRIAGE 
Early risk stratification is important to classify a patient’s risk (low, intermediate and high), 
and to identify which STEMI patients benefit from early interventions, that is, patients who 
present early benefit the most from reperfusion therapy. Conversely, patients who present 
late are at lower risk, have already survived the pre-hospital phase and benefit less from 
reperfusion therapy [5, w3]. It was demonstrated that high-risk patients benefit the most 
from short door-to-balloon (D2B) times [w4].  
Several risk scores have been developed to classify a STEMI patient’s ischaemic risk, of which 
the TIMI risk score and the GRACE risk score are the most known and adopted ones [w5-w6]. 
However, these risk models are bedside scores used in-hospital to predict mortality. Morrow 
et al have developed a simple risk index based on age, heart rate and systolic blood pressure 
for predicting 30-day mortality [6]. This is the only risk score known for STEMI patients which 
can  be  used in the  pre-hospital phase.  Additionally, it is known that older  age, higher Killip 
13
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 class, anterior infarction, elevated heart rate, lower systolic blood pressure, or new left bundle 
branch block play a pivotal role in the judgement of a patients’s risk in the pre-hospital phase. 
Besides these indicators, recently, the predicting value on clinical outcome of specific markers 
in the pre-hospital phase, like the extent of ST segment deviation, grade of ischaemia and 
QRS width, are of great interest in STEMI patients. 
 
TIME DELAYS 
Time is very important in the treatment of STEMI patients [7]. The time from symptom onset 
(SO) until balloon inflation (BI), defined as ischaemic time, is crucial for patient outcome. 
Since the time from SO until first medical contact (FMC), the so-called ‘patient delay’, is 
hampered by recall and information bias and confounding, recently more attention has been 
paid to the new phrase ‘systemdelay’ (FMC-reperfusion therapy) and its derivates (Figure 2).  
 
 
Figure 2. The different time delays are demonstrated for ST elevation myocardial infarction  
(STEMI) patients for patients treated with pre-hospital diagnosis and triage in the ambulance (A)  
and treated with pre-hospital diagnosis and triage in the referral non-percutaneous coronary  
intervention (PCI) centre (B).  
BI, balloon inflation; DIDO, door-in-door-out time; D2B, door-to-balloon time; EMS,  
emergency medical services; min: minutes. 
 
A longer ‘system-delay’ is associated with a higher mortality [8] Furthermore, several studies 
have focused on decreasing the D2B time. A shorter D2B time is associated with improved 
outcome [9-10]. Since not all STEMI patients are directly transferred to a PCI centre, but are 
first transported to a non-PCI centre, the door-in-door-out (DIDO) time has recently been 
described as a clinical performance measurement. A shorter DIDO time is associated with 
shorter reperfusion delays and lower in-hospital mortality [w7]. Previous studies showed that 
optimising logistics by pre-hospital diagnosis and triage in the ambulance can help to reduce 
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 treatment delays and improve outcomes [3, 11, 12, w8-w12]. Especially at longer distance 
from the patient’s residence to the PCI centre, pre-hospital diagnosis and triage in the 
ambulance was associated with a shorter time to treatment, and a more favourable outcome, 
compared with referral via a non-PCI referral centre [2]. 
 
PRE-HOSPITAL TREATMENT STRATEGIES 
The pre-hospital treatment for STEMI patients has been improved during the last decade. Pre-
hospital thrombolytic therapy and new antiplatelet and antithrombotic agents were developed 
(Table 1).  
 
Table 1. Overview of medical treatment strategies for STEMI patients in the pre-hospital phase versus 
the in-hospital phase 
Agents with proven efficacy in the 
pre-hospital phase 
Study and/or authors Study design 
Thrombolytic therapy - The European Myocardial   
  Infarction Project Group 
- Bjorklund et al.  
- Multicentre, double blind trial 
 
- Prospective cohort study 
High dose heparin   HEAP trial, Liem et al.   Single centre, open-label trial 
Aspirin and heparin   Zijlstra F et al.    Cohort study 
Aspirin, heparin/enoxaparin and 
clopidogrel 
  CIPAMI trial, Zeymer U et al.    Multi-centre, randomized, open trial.  
Aspirin, heparin, clopidogrel and 
tirofiban 
 On-TIME trial, Van ‘t Hof et   
 al.    
  Multi-centre, randomized, double   
  blind, placebo controlled clinical trial 
Aspirin, heparin, clopidogrel and 
abciximab 
  EGYPT-ALT, De Luca et al.    Meta-analysis 
Future   
Aspirin, heparin and ticagrelor   Atlantic trial  Multi-centre, randomized, parallel- 
 group, double blind, placebo controlled   
 clinical trial 
Aspirin, P2Y12 blocker and bivalirudin   Euromax trial  Multi-centre, randomized, open-label  
 clinical trial 
 
Pre-hospital thrombolytic therapy  
The introduction of thrombolytic therapy was a major improvement in the treatment of STEMI 
patients. Pre-hospital treatment with thrombolytic therapy reduced time to treatment by 1 h, 
and mortality by 17% compared with in-hospital thrombolytic therapy [13]. In a more recent 
analysis, it was shown that pre-hospital diagnosis and thrombolysis with trained paramedic 
personnel in the ambulance was associated with a shorter time to treatment, and a 30% 
reduced relative mortality risk compared with in-hospital thrombolysis [14]. In a randomised 
trial, Bonnefoy et al compared pre-hospital thrombolysis with primary PCI and found no 
difference in mortality or re-infarction [w13]. However, in the subgroup of patients who were 
treated within 2 h after SO, pre-hospital thrombolytic therapy reduced long term mortality 
[15]. Since multiple reports demonstrated a superior effect of primary PCI compared with 
15
1
 thrombolytic therapy, the latter therapy is only recommended in STEMI patients if the time 
from first medical contact balloon inflation time (FMC-BI) is more than 120 min (ESC) or more 
than 90 min (AHA) [w1-w2].  
 
Antiplatelet and antithrombotic agents  
Effective platelet inhibition is a cornerstone in the therapy of STEMI patients. The pre-hospital 
treatment effect of aspirin has not been studied individually. The only performed study 
investigating the effect of aspirin in STEMI patients was the ISIS-2 trial; however, this trial 
was not performed pre- versus in-hospital [w14]. The pre-hospital treatment effect of both 
aspirin and heparin was studied years ago and has been proven to be effective [16-17]. 
Upstream treatment with glycoprotein (Gp) IIb/IIIa inhibitors are administered pre-hospitally 
to STEMI patients. Pre-hospital versus in-hospital administration of tirofiban improved TIMI 2-
3 flow pre-PCI and myocardial reperfusion in STEMI patients [18]. In the On-TIME 2 trial, 
early tirofiban administration was associated with improved pre and post-procedural 
reperfusion and improved clinical outcome as well [19]. Especially when administered in the 
golden hour, a concept adopted from thrombolytic studies, the effect of triple antiplatelet 
pretreatment, including tirofiban, was most effective [20]. In the On-TIME 2 trial, pre-hospital 
initiation of high-dose tirofiban significantly increased the number of patients with an aborted 
myocardial infarction, especially in patients with <70 min of symptoms. Studies performed 
with upstream administration of abciximab have shown comparable results [21]. Despite this 
evidence, the most recent guideline on myocardial revascularisation states that upstream 
treatment with Gp IIb/IIIa inhibitors is not recommended (class III recommendation). This 
recommendation is based on the negative results of abciximab facilitated PCI in the FINESSE 
trial [w15]. There is still no consensus about the pre-hospital versus in-hospital treatment 
effect of clopidogrel in addition to aspirin and heparin on outcome. The only randomised trial 
performed by Zeymer et al was stopped prematurely [22]. Newer antiplatelet agents like 
ticagrelor and prasugrel are nowadays also administered pre-hospitally to STEMI patients 
instead of clopidogrel; however, the effect of these agents needs to be further evaluated since 
the trials performed did not investigate the pre-treatment versus in-hospital treatment effect. 
A dedicated trial evaluating the effect of in-ambulance ticagrelor is currently running. Effects 
of direct thrombin inhibitors are also of great interest these days. Therefore, currently, a 
randomised trial to evaluate the effect of bivalirudin is performed. Overall, more research is 
needed to assess the efficacy of pre-treatment versus in-hospital treatment of the new 
antiplatelet and antithrombotic agents. In the near future, the pharmacological agents will 
probably be more tailored to the patient, considering the interindividual variability in response 
to antiplatelet and antithrombotic agents, and the patient’s risk of bleeding. 
 
CONCLUSION 
A wide variety of therapeutic options are available for the pre-hospital care of STEMI patients. 
Optimisation of the care can be achieved by better logistics, risk assessment and triage. In 
16 17
 addition, early diagnosed STEMI in the ambulance is the ideal environment for initiating 
effective antiplatelet and/or antithrombotic treatment early after the onset of symptoms. This 
treatment might become further tailored to the individual patient in the future. 
17
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OUTLINE OF THE THESIS 
This thesis addresses two important issues. PART I of the thesis focuses on the pre-hospital 
diagnosis and triage in the ambulance (field triage) and pre-hospital treatment of STEMI 
patients. In PART II electrocardiographic parameters of the diagnostic ECG of STEMI patients 
at risk were investigated.  
 
The aim of PART I of the thesis was to determine how field triage and pre-hospital treatment 
of STEMI patients can be improved leading to better angiographic and clinical outcome for 
these patients.  
Chapter 2 and 3 concern the relation between referral of STEMI patients via field triage versus 
referral via non-PCI centre by means of a cohort  study (chapter 2) and a systematic review 
(chapter 3) with outcome. Chapter 4 demonstrates the influence of residential distance from a 
PCI centre on ischemic time in STEMI patients. In chapter 5 the relation between system 
delay and mortality for patients with an anterior versus non-anterior STEMI was investigated. 
Chapter 6 addresses whether early ambulance initiation of high dose clopidogrel in STEMI 
patients improves angiographic and clinical outcome compared to cathlab initiation.  
 
The aim of PART II of the thesis was to determine which parameters of the diagnostic ECG 
are predictors for STEMI patients at high risk in the acute phase. 
Chapter 7 addresses which baseline characteristics of STEMI patients are predictors for grade 
3 ischemia (G3I) and the effect of G3I on outcome was investigated. Chapter 8 concerns the 
predictive value of initial ST-segment deviation in STEMI patients compared to ST-segment 
elevation. 
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 ABSTRACT 
 
BACKGROUND 
We evaluated the effect of pre-hospital triage (PHT) in the ambulance on infarct size and 
clinical outcome and studied its relationship to the distance of patient’s residence to the 
nearest percutaneous coronary intervention (PCI) centre.  
 
METHODS 
All consecutive ST-segment elevation myocardial infarction (STEMI) patients who were 
transported to the Isala klinieken from 1998 until 2008 were registered in a dedicated 
database. Of these, 2288 (45%) were referred via a spoke centre and 2840 (55%) via PHT.  
 
RESULTS 
PHT patients were more often treated within three hours after symptom onset (46.2% vs. 
26.8%, p<0.001), more often had a post procedural TIMI 3 flow (93.0% vs. 89.7%, 
p<0.001), had a smaller infarct size (peak CK: 2188 ± 2187 vs. 2575 ± 2259 IU/l, p<0.001) 
and had a lower one-year mortality (4.9% vs. 7.0%, p=0.002). After multivariate analysis, 
PHT was independently associated with ischemic time less than three hours (OR: 2.45, 95% 
CI 2.13 to 2.83), a peak CK less than the median value (OR: 1.19, 95% CI 1.04 to 1.36) and 
a lower one-year mortality (OR:0.67, 95% CI 0.50 to 0.91). The observed differences 
between PHT patients and the spoke group were more pronounced in the subgroup of patients 
living >38 km from the PCI centre.  
 
CONCLUSION 
PHT in the ambulance is associated with a shorter time to treatment, a smaller infarct size 
and a more favourable clinical outcome, especially with longer distance from the patient’s 
residence to the nearest PCI centre. Therefore, PHT in the ambulance may reduce the 
negative effect of living at a longer distance from the PCI centre. 
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 INTRODUCTION 
It is well known that rapid restoration of coronary blood flow in patients with ST-segment 
elevated myocardial infarction (STEMI) is crucial [1] to limit myocardial damage [2-3]. There 
are two established therapeutic strategies to achieve this: fibrinolysis and primary 
Percutaneous Coronary Intervention (pPCI), of which the latter is considered more effective 
[2, 4-7]. However, there is still debate about the time interval during which pPCI can be 
recommended. According to the American Heart Association/American College of Cardiology 
(AHA/ACC) pPCI is preferred if the delay between first medical contact and pPCI does not 
exceed 90 minutes (min) [8] and according to the European Society of Cardiology (ESC) this 
delay should not exceed 120 minutes (min) [9]. If the anticipated delay exceeds 90 min 
(AHA/ACC) or 120 min (ESC), fibrinolytic therapy may be an alternative, since it can be 
administered with a shorter delay in the ambulance or in a nearby spoke centre [10-11]. 
One of the possibilities to shorten delays and maximise the number of patients eligible for 
pPCI, is to transport STEMI patients directly to a PCI centre after pre-hospital triage (PHT) in 
the ambulance. Several studies have shown that this strategy can significantly reduce 
ischemic times compared to patients being referred via a spoke centre [12-15]. Recently, 
Pedersen et al. have demonstrated that PHT also improves outcome [15]. However, a recent 
analysis from the HORIZONS AMI study did not show a benefit for patients immediately 
transported to a PCI centre [16]. In addition, it is less well known if PHT is beneficial for 
patients living at a greater distance from a PCI centre. Therefore, we addressed both the 
question on efficacy and on distance in a large cohort of non-selected STEMI patients, who 
were directed to our centre either via a referral centre (spoke) or via PHT. 
 
METHODS 
Population 
Since the early nineties STEMI patients referred to the Isala Klinieken were treated by pPCI. 
To improve the logistics of STEMI patients, the PHT project was initiated. This has gradually 
been implemented in the region, starting in 1998. At that time thirteen spoke centres referred 
their STEMI patients to our PCI centre, however this number decreased to eight spoke centres 
since new PCI centres opened. During the project all consecutive STEMI patients who were 
transported to our PCI-centre from 1998 until 2008 and underwent pPCI, were prospectively 
registered in a dedicated database. Criteria for the diagnosis of STEMI were: (1) history of 
cardiac symptoms of at least 10 min in the last 24 hours prior to presentation at the spoke or 
PCI centre, (2) elevated levels of Creatin Kinase (CK) or Creatin Kinase-MB (CKMB) and (3) 
concurrent electrocardiogram (ECG) changes: ST-segment elevation of >1mV in at least two 
adjacent electrocardiogram leads [17]. Information whether patients were transferred via 
referral centres (spoke group) in the network or via PHT (PHT group) was recorded. In 
addition information on infarct size, angiographic outcome and short and long term clinical 
outcome were registered as well. Infarct size was calculated as the peak level of CK (peak CK) 
within 48 hours after admission [18].  
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 The distance via motorway to the nearest PCI centre was computerized using the postal codes 
of the patient’s residence and the PCI centre. Subsequently the percentiles (25-75) of the 
computed distances were calculated. The PHT and spoke group were subdivided in short (≤38 
km) and long distance (>38 km) based on the median distance from patient’s residence to 
the PCI centre.  
Patients were excluded if they did not have a confirmed diagnosis of acute myocardial 
infarction (CK <200 and no evidence of unstable plaque or culprit lesion at coronary 
angiography), the distance from patient’s residence to the PCI centre was not available or if 
the distance from patient’s residence to the PCI centre was ≥120 km (outer bound of 
referring area). 
 
Triage for pPCI 
PHT: 
The algorithm of PHT has been described previously [19]. In brief: After patients dialed the 
emergency number, patients were triaged in the ambulance, if the ambulance was equipped 
with the PHT equipment. If STEMI was suspected, an ECG was made by highly trained 
paramedics and the computerised algorithm revealed an outcome. If a diagnosis of STEMI 
was made, the ambulance went straight to the catheterization laboratory of PCI centre, 
bypassing the emergency departments of the spoke centre.  
 
Spoke: 
If the ambulance was not equipped with the PHT equipment, the ambulance went to the 
nearest spoke centre where diagnosis and triage was performed. For diagnosis, an ECG was 
made immediately upon arrival. In case of a STEMI diagnosis, patients were transported to 
the catheterization laboratory of the PCI centre as soon as possible.  
 
Walk-ins at the PCI centre were excluded since they did not receive pre-hospital triage.  
 
pPCI procedure 
In both situations (PHT and Spoke), the staff of the catheterization laboratory of the PCI-
centre was pre-informed about the estimated time of arrival of the patient and was activated 
well before the arrival of the patient. In case the staff lived more than 30 min away from the 
PCI centre, they had to stay in the PCI centre when being on-call. Patients were pre-treated 
with an intravenous bolus of 5000 IU unfractionated heparin, 500 mg aspirin intravenously 
and subsequently with 600 mg clopidogrel and/or tirofiban (25 µg/kg bolus, 0.15 µg/kg/min 
maintenance infusion). PHT patients were pre-treated in the ambulance and spoke patients 
were pre-treated at the spoke centre and/or in the ambulance which transferred the patient 
form the spoke centre to the PCI centre.  
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 Time intervals 
Six different time intervals were evaluated:1.Time from symptom onset (SO) to infarct 
diagnosis (time diagnostic ECG) either in the ambulance or at a spoke centre (SO-Diagnosis) 
2.Time from diagnosis till arrival at the PCI centre (Diagnosis-Door PCI) 3.Time from 
diagnosis to balloon inflation (BI) (Diagnosis-BI) 4.Time from arrival spoke centre to arrival 
PCI centre (Door-to-door:D2D) 5.Time from arrival at the PCI centre to BI for PHT patients 
and time from arrival spoke hospital to BI for spoke patients (Door-to-balloon: D2B) and 
6.Total ischemic time defined as the time from SO to BI.  
 
Statistical analysis 
Statistical analysis was performed with SPSS 17.0. Continuous data were expressed as mean 
± SD or median and interquartile range. Categorical data were presented as percentage. 
ANOVA was used for continuous data and Pearson’s Chi-square test was used for the 
categorical data, respectively. We tested the associations between the variable ‘PHT’ and 
other baseline characteristics using univariate logistic regression. The Mann-Whitney test has 
been used to calculate the time intervals between the PHT group and the spoke group, since 
they were non-Gaussian distributed. To assess independent predictors of PHT, multivariate 
analysis was performed using a logistic regression analysis. In this analysis, univariate 
variables with a p-value <0.10 were included. In all the statistical analyses p-values ≤0.05 
were considered as statistical significant.  
 
The study was conducted according to the principles of the Declaration of Helsinki and the 
protocol was approved by the local institutional review board. No extramural funding was 
used to support this work. The authors are solely responsible for the design and conduct of 
this study, all study analyses and drafting and editing of the paper.  
 
RESULTS 
Ambulance triage versus referral by spoke centre 
From 1998, the first year of implementation of PHT in the ambulance, until 2008 5674 
patients were referred to our institution with the intention to perform pPCI. Three hundred 
and twenty three patients (5.7%) were false positives (PHT and spoke patients) and 223 
patients (3.9%) were walk-ins at the PCI centre. From the remaining 5128 patients who 
actually underwent pPCI, 2288 patients (45%) were referred via a spoke centre and 2840 
patients (55%) via PHT.  
Patients from the spoke group were younger, more often smoked, more often had 
hypercholesterolemia, more often had a previous myocardial infarction (MI), more often 
presented in Killip class >1 and less often had previous coronary artery bypass grafting 
(CABG) (Table 1). The median distance from patient’s residence to the nearest PCI centre was 
38 km (25-49), 28 km (16-41) for the PHT group and 43 km (37-60) for the spoke group 
(p<0.001). The different time intervals for the two groups are presented in Figure 1.  
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Figure 1. The different time intervals are shown for the total group, for patients living ≤38 km from a PCI 
centre and for patients living >38 km from a PCI centre. These groups were subdivided for PHT and spoke 
patients. 
 
 
Table 1. Baseline characteristics   
Characteristic Total 
(N=5128) 
PHT 
(N=2840) 
Spoke 
(N=2288) 
P  
Age years ± SD 62.17±12.14 62.80±12.12 61.40±12.12 <0.001 
Male gender 3800/5125 (74.1%) 2110/2838 (74.3 %)  1690/2287 (73.9%)   0.713 
Risk factors     
Hypertension 1668/5063 (32.9%) 926/2811 (32.9%) 742/2252 (32.9%)   0.996 
Diabetes Mellitus 557/5108 (10.9%) 296/2833 (10.4%) 261/2275 (11.5%)   0.243 
Smoking 2433/5015 (48.5%) 1310/2785 (47.0%) 1123/2230 (50.4%)   0.019 
Hypercholesterolemia 1085/4852 (22.4%) 563/2682 (21.0%) 522/2170 (24.1%)   0.011 
Family history 2058/4928 (41.8%) 1151/2731 (42.1%) 907/2197 (41.3%)   0.542 
Killip class >1 346/5098 (6.8%) 171/2831 (6.0%) 175/2267 (7.7%)   0.018 
Previous MI 499/5109 (9.8%) 232/2830 (8.2%) 267/2279 (11.7%) <0.001 
Previous PCI 364/5074 (7.2%) 214/2821 (7.6%) 150/2253 (6.7%)   0.203 
Previous CABG 132/5119 (2.6%) 84/2837 (3.0%) 48/2282 (2.1%)   0.054 
Previous CVA 146/5114 (2.9%) 78/2834 (2.8%) 68/2280 (3.0%)   0.623 
TIMI risk score 2.16±1.82  2 (1-3) 2.17±1.84  2 (1-3) 2.15±1.80  2 (1-3)   0.948 
PHT:pre-hospital triage group, Spoke:spoke group, SD:standard deviation, MI:myocardial infarction, 
PCI:percutaneous coronary intervention, CABG:coronary artery bypass graft, CVA:cerebro vascular accident, 
TIMI:thrombolysis in myocardial infarction. 
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Table 2. Distance, total ischemic time, indication pPCI and distance of patients home to PCI centre 
 PHT Spoke P  
Total 
Distance (km)* 
Ischemic Time (median, IQR, N=2728) 
Ischemic Time <3 hrs (%, N=5028) 
SO - Diagnosis (median, IQR, N=2531) 
Diagnosis - Door PCI (median, IQR, N=1982) 
Diagnosis - BI (median, IQR, N=2625) 
D2D (median, IQR, N=984) 
D2B (median, IQR, N=2664) 
Indication pPCI AHA/ACC (%, N=2625) 
Indication pPCI ESC (%, N=2625) 
 
Distance home-PCI centre ≤38 km 
Distance (km)* 
Ischemic Time (median, IQR, N=1308) 
Ischemic Time <3 hrs (N=2522) 
SO - Diagnosis (median, IQR, N=1206) 
Diagnosis - Door PCI (median, IQR, N=974) 
Diagnosis - BI (median, IQR, N=1240) 
D2D (median, IQR, N=285) 
D2B (median, IQR, N=1266) 
Indication pPCI AHA/ACC (%, N=1245) 
Indication pPCI ESC (%, N=1245) 
 
Distance home-PCI centre >38 km 
Distance (km)* 
Ischemic Time (median, IQR, N=1420) 
Ischemic Time <3 hrs (%, N=2506) 
SO - Diagnosis (median, IQR, N=1325) 
Diagnosis - Door PCI (median, IQR, N=1326) 
Diagnosis - BI (median, IQR, N=1358) 
D2D (median, IQR, N=699) 
D2B (median, IQR, N=1398) 
Indication pPCI AHA/ACC (%, N=1385) 
Indication pPCI ESC (%, N=1385) 
 
28.1 (15.9-14.8) 
184 (140-274) 
1285/2784 (46.2%) 
82 (47-150) 
52 (37-68) 
94 (77-119) 
 
44 (30-69) 
719/1637 (43.9%) 
1230/1637 (75.1%) 
 
 
19.0 (13.1-29.0) 
187 (139-282) 
850/1908 (44.5%) 
87 (49-158) 
46 (33-61) 
90 (74-118) 
 
46 (31-74) 
484/962 (49.7%) 
731/962 (76.0%) 
 
 
45.9 (41.0-63.0) 
180 (142-256) 
435/876 (49.7%) 
76 (45-136) 
60 (45-79) 
101 (82-122) 
 
40 (27-61) 
241/675 (35.7%) 
488/675 (73.9%) 
 
42.6 (37.3-59.9) 
260 (187-393) 
601/2244 (26.8%)  
129 (68-252) 
83 (59-116) 
123 (98-160) 
85 (60-123) 
132 (101-189) 
173/988 (17.5%) 
466/988 (47.2%) 
 
 
32.6 (26.8-36.0) 
255 (177-407) 
171/614 (27.9%) 
132 (69-259) 
78 (54-114) 
118 (93-159) 
78 (53-120) 
127 (98-198) 
56/283 (20.1%) 
149/283 (52.7%) 
 
 
49.6 (41.6-66.7) 
261 (190-391) 
430/1630 (26.4%) 
125 (66-251) 
85 (61-117) 
124 (100-160) 
89 (62-126) 
133 (103-188) 
117/710 (16.5%) 
322/710 (45.4%) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
 
 
<0.001 
<0.001 
<0.001       
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
*Data expressed as median and IQR. 
AHA/ACC:American Heart Association/American College of Cardiology, ESC:European Society of  
Cardiology, pPCI:primary percutaneous coronary intervention, PHT:pre-hospital triage group, 
Spoke:spoke group, IQR:interquartile range, SO:symptom onset, PCI:percutaneous coronary  
intervention, BI:balloon inflation, D2D:door-to-door time, D2B:door-to-balloon time. 
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 Table 3. Angiographic and clinical outcome 
 PHT (N=2840) Spoke (N=2288) P  
Total 
TIMI 3 flow pre-PCI 
TIMI 3 flow post-PCI 
Infarct size ± SD *(IU/l, N=4986) 
30-day mortality 
One-year mortality 
 
Distance residence-PCI centre ≤38 km 
TIMI 3 flow pre-PCI 
TIMI 3 flow post-PCI 
Infarct size ± SD *(IU/l, N=2482) 
30-day mortality  
One-year mortality 
 
Distance residence-PCI centre >38 km 
TIMI 3 flow pre-PCI 
TIMI 3 flow post-PCI  
Infarct size ± SD *(IU/l, N=2504) 
30-day mortality  
One-year mortality 
 
570/2826 (20.2%) 
2625/2822 (93.0%) 
2188±2187 
86/2798 (3.1%) 
134/2729 (4.9%) 
 
 
359/1935 (18.6%) 
1792/1932 (92.8%) 
2154±2161 
60/1913 (3.1%) 
98/1878 (5.2%) 
 
 
211/891 (23.7%) 
833/890 (93.6%) 
2261±2241 
26/885 (2.9%) 
36/851 (4.2%) 
 
423/2286 (18.5%) 
2042/2276 (89.7%) 
2575±2259 
90/2249 (4.0%) 
151/2164 (7.0%) 
 
 
125/626 (20.0%) 
561/623 (90.0%) 
2359±2146 
28/615 (4.6%) 
41/581 (7.1%) 
 
 
298/1660 (18.0%) 
1481/1653 (89.6%) 
2656±2295 
62/1634 (3.8%) 
110/1583 (6.9%) 
   
  0.134 
<0.001 
<0.001 
  0.074 
  0.002 
 
 
  0.432 
  0.030 
  0.054 
  0.096 
  0.094 
 
 
<0.001  
<0.001 
<0.001 
  0.264 
  0.007 
*peak CK  
PHT:pre-hospital triage group, Spoke:spoke group, TIMI:thrombolysis in myocardial infarction, 
PCI:percutaneous coronary intervention, CK:Creatin Kinase. 
 
Total median ischemic time was 209 min, 184 min for the PHT group and 260 min for the 
spoke group (p<0.001). The percentage of patients treated within three hours of SO was 
46.2% in the PHT group compared to 26.8% in the spoke group (p<0.001) (Table 2). The 
time from SO-Diagnosis was shorter for the PHT group as compared to the spoke group (82 
vs. 129 min p<0.001). The median D2D for the spoke group was 85 min. The D2B was longer 
for the spoke group as compared to the PHT group (132 vs. 44 min, p<0.001).  
Significantly more patients of the PHT group were treated according to the most recent 
guidelines of the AHA/ACC and the ESC as compared to the spoke group (AHA/ACC:PHT 
43.9% vs. spoke 17.5%, ESC:PHT 75.1% vs. spoke 47.2%, p<0.001 for both comparisons) 
(Table 2) [8-9]. 
PHT patients had also better angiographic and clinical outcome. They more often had post 
procedural TIMI 3 flow (93.0% vs. 89.7%, p<0.001), had a smaller infarct size (peak CK: 
2188 ± 2187 vs. 2575 ± 2259 IU/l, p<0.001) and a lower one-year mortality (4.9% vs. 
7.0%, p=0.002) (Table 3). 
After correction for differences in baseline characteristics, including the difference in distance, 
PHT was independently associated with an ischemic time of less than three hours (OR: 2.45, 
95% CI 2.13 to 2.83), infarct size of less than the median value (OR: 1.19, 95% CI 1.04 to 
1.36) and a lower one-year mortality (OR: 0.67, 95% CI 0.50 to 0.91) (Table 4).  
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 Distance to PCI centre 
Figure 1 illustrates the time intervals in association with the distance from the patient’s 
residence to the PCI centre. PHT patients had a shorter time from SO-Diagnosis irrespective 
of distance to the PCI centre. Surprisingly, total ischemic time was even somewhat shorter in 
the PHT patients living at a distance >38 km as compared to ≤38 km. For both groups 
however, the time from Diagnosis-Door PCI was longer for patients living at a greater 
distance from the PCI centre (PHT from 44 min to 55 min, spoke from 78 min to 89 min, 
p<0.001 for both comparisons).  
A longer distance led to a decrease in the percentage of patients treated according to the 
guidelines of the AHA/ACC (≤38 km: 540/1245 (43.4%) vs. >38 km: 358/1385 (25.6%), 
p<0.001) and the ESC (≤38 km: 880/1245 (70.7%) vs. >38 km: 810/1385 (58.5%), 
p<0.001) (Table 2) [8-9].  
In patients living ≤38 km from the PCI centre, apart from a higher post procedural TIMI 3 
flow in the PHT group, no significant differences in angiographic parameters, infarct size or 
clinical outcome were found. However, in patients living >38 km away from the PCI centre, 
PHT patients  more often had a higher initial and post procedural TIMI 3 flow, had a smaller 
infarct size and had a lower one-year mortality compared to the spoke group (Table 3).  
 
DISCUSSION 
So far, this is the largest study showing that PHT in the ambulance with immediate 
transportation to the nearest PCI centre results in a shorter time to treatment, a reduction in 
infarct size and a better angiographic and clinical outcome as compared to referral via a spoke 
centre. This was most evident for patients living at greater distance from the PCI centre. In 
addition, PHT significantly increased the number of patients treated according to the AHA/ACC 
and the ESC guidelines [8-9]. These results suggest that living at a longer distance from a PCI 
centre may not negatively influence angiographic and clinical outcomes when PHT is available. 
Our study showed that 43.9% and 75.1% of the patients fulfil the AHA/ACC respectively the 
ESC criteria for pPCI when PHT is available. When diagnosis and triage was performed at a 
spoke centre, only 17.5% (AHA/ACC) and 47.2% (ESC) of the patients were treated according 
to the guidelines. Figure 1 shows that the largest difference between the groups is seen in the 
time from SO-Diagnosis. Due to the fact that the ambulance which brought the patient 
initially to a spoke center was not able to make the infarct diagnosis (no trained personnel, no 
ECG equipment), diagnosis was only made after arrival of the patient in the spoke centre at a 
median of 125 min after SO, whereas after PHT, diagnosis was made 49 min (39%) earlier. 
This earlier diagnosis, together with the early initiation of potent anti-platelet and anti-
thrombotic agents in the ambulance (unfractionated heparin, aspirin and clopidogrel), may 
have led to the higher initial patency and better angiographic outcome in PHT patients [20]. 
Despite the fact that all efforts were taken to arrange further or a new transport to the PCI 
centre as soon as possible, the Diagnosis-Door PCI time was considerably longer in the spoke 
group as compared to the Diagnosis-Door PCI time in the PHT group (83 vs. 52 min, 
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 p<0.001) (Figure 1). As a consequence, the D2B time was significantly longer for the spoke 
group as compared to the PHT group (132 min vs. 44 min, p<0.001). These findings 
correspond with the results of Le May et al. [21].  
 
Table 4. Output multivariate analyses 
Treatment within three hours Infarct size < median One-year mortality 
Variables OR (95% CI) Variables OR (95% CI) Variables OR (95% CI) 
Type triage 2.45 (2.13-2.83) Type triage 1.19 (1.04-1.36) Type triage 0.67 (0.50-0.91)  
Gender 1.21 (1.04-1.41) Gender 0.67 (0.58-0.78) Gender 0.90 (0.66-1.21) 
Hypertension 1.20 (1.04-1.41) Hypertension 0.96 (0.84-1.10) Hypertension 1.42 (1.06-1.92) 
Family history 1.04 (0.91-1.18) Hyperchol 0.99 (0.85-1.16) Hyperchol 0.63 (0.43-0.93) 
DMII 1.01 (0.81-1.26) Smoking 0.86 (0.75-0.98) DMII 1.06 (0.72-1.57) 
Age 1.03 (1.02-1.04) Age 1.01 (1.00-1.01) Age 1.04 (1.02-1.05) 
TIMI risk score 0.61 (0.57-0.65) Previous MI  1.29 (1.01-1.65) TIMI risk score 1.21 (1.09-1.35) 
Previous CABG 0.70 (0.46-1.08) Previous CABG 1.03 (0.58-1.83) Family history 0.70 (0.51-0.96) 
Previous PCI 1.55 (1.21-1.99) Previous PCI 1.47 (1.12-1.93) Previous MI 1.23 (0.90-1.67) 
IRV:LAD 1.27 (1.13-1.47) Killip class >1 0.61 (0.47-0.78) Pervious CVA 2.29 (1.28-4.10) 
Distance 1.00 (1.00-1.00) IRV:CX 2.10 (0.67-6.64) Killip class >1 3.07 (1.99-4.72) 
  IRV:graft 3.98 (1.02-15.6) Distance 1.00 (0.99-1.01) 
  IRV:LAD 1.85 (0.59-5.81) IRV:LAD 1.05 (0.80-1.39) 
  IRV:RCA 4.05 (1.29-12.7)  
  Distance 0.99 (0.99-1.00) 
CABG, Coronary artery bypass grafting; CX, circumflex; DMII, diabetes mellitus type II; IRV, infarct related 
vessel; LAD, left anterior descendents; MI, myocardial infarction; RCA, right coronary artery. 
Effect of Distance 
Our study shows that time to treatment is substantially reduced by pre-hospital triage in the 
ambulance and shows that incorporating this triage significantly increases the number of 
patients who are candidates for primary angioplasty instead of thrombolysis according to the 
guidelines, especially for patients who live further than 38 km away from a PCI centre. These 
findings suggest that the logistics of arranging diagnosis and immediate transportation is 
more important than the distance of the patient’s residence from a PCI centre: for PHT 
patients, total ischemic times remained very short despite a longer distance from the PCI 
centre. A longer distance from the patients’ residence to the PCI centre had very limited effect 
on total ischemic time despite a significantly increased Diagnosis-Door PCI time. This was due 
to a shorter SO-Diagnosis time.  
Other investigators have also studied the effect of distance on clinical outcome in STEMI 
patients. In a cohort study, Wei et al. demonstrated that patients with a first myocardial 
infarction who were living at more than nine miles (14.5 km) from the PCI centre had a higher 
mortality compared to patients who lived closer to the PCI centre [22]. Nevertheless, in our 
study the effect of distance on outcome was related to the type of patient triage, which was 
not reported in the study from Wei et al.  
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p<0.001) (Figure 1). As a consequence, the D2B time was significantly longer for the spoke 
group as compared to the PHT group (132 min vs. 44 min, p<0.001). These findings 
correspond with the results of Le May et al. [21].  
 
Table 4. Output multivariate analyses 
Treatment within three hours Infarct size < median One-year mortality 
Variables OR (95% CI) Variables OR (95% CI) Variables OR (95% CI) 
Type triage 2.45 (2.13-2.83) Type triage 1.19 (1.04-1.36) Type triage 0.67 (0.50-0.91)  
Gender 1.21 (1.04-1.41) Gender 0.67 (0.58-0.78) Gender 0.90 (0.66-1.21) 
Hypertension 1.20 (1.04-1.41) Hypertension 0.96 (0.84-1.10) Hypertension 1.42 (1.06-1.92) 
Family history 1.04 (0.91-1.18) Hyperchol 0.99 (0.85-1.16) Hyperchol 0.63 (0.43-0.93) 
DMII 1.01 (0.81-1.26) Smoking 0.86 (0.75-0.98) DMII 1.06 (0.72-1.57) 
Age 1.03 (1.02-1.04) Age 1.01 (1.00-1.01) Age 1.04 (1.02-1.05) 
TIMI risk score 0.61 (0.57-0.65) Previous MI  1.29 (1.01-1.65) TIMI risk score 1.21 (1.09-1.35) 
Previous CABG 0.70 (0.46-1.08) Previous CABG 1.03 (0.58-1.83) Family history 0.70 (0.51-0.96) 
Previous PCI 1.55 (1.21-1.99) Previous PCI 1.47 (1.12-1.93) Previous MI 1.23 (0.90-1.67) 
IRV:LAD 1.27 (1.13-1.47) Killip class >1 0.61 (0.47-0.78) Pervious CVA 2.29 (1.28-4.10) 
Distance 1.00 (1.00-1.00) IRV:CX 2.10 (0.67-6.64) Killip class >1 3.07 (1.99-4.72) 
  IRV:graft 3.98 (1.02-15.6) Distance 1.00 (0.99-1.01) 
  IRV:LAD 1.85 (0.59-5.81) IRV:LAD 1.05 (0.80-1.39) 
  IRV:RCA 4.05 (1.29-12.7)  
  Distance 0.99 (0.99-1.00) 
CABG, Coronary artery bypass grafting; CX, circumflex; DMII, diabetes mellitus type II; IRV, infarct related 
vessel; LAD, left anterior descendents; MI, myocardial infarction; RCA, right coronary artery. 
Effect of Distance 
Our study shows that time to treatment is substantially reduced by pre-hospital triage in the 
ambulance and shows that incorporating this triage significantly increases the number of 
patients who are candidates for primary angioplasty instead of thrombolysis according to the 
guidelines, especially for patients who live further than 38 km away from a PCI centre. These 
findings suggest that the logistics of arranging diagnosis and immediate transportation is 
more important than the distance of the patient’s residence from a PCI centre: for PHT 
patients, total ischemic times remained very short despite a longer distance from the PCI 
centre. A longer distance from the patients’ residence to the PCI centre had very limited effect 
on total ischemic time despite a significantly increased Diagnosis-Door PCI time. This was due 
to a shorter SO-Diagnosis time.  
Other investigators have also studied the effect of distance on clinical outcome in STEMI 
patients. In a cohort study, Wei et al. demonstrated that patients with a first myocardial 
infarction who were living at more than nine miles (14.5 km) from the PCI centre had a higher 
mortality compared to patients who lived closer to the PCI centre [22]. Nevertheless, in our 
study the effect of distance on outcome was related to the type of patient triage, which was 
not reported in the study from Wei et al.  
 According to a recent study, D2B may also be reduced by performing pPCI at a PCI centre 
without on-site cardiac surgery [23]. However, this study was stopped prematurely and a 
third arm with routine ambulance triage was lacking [24]. It might therefore be true that the 
opening of extra PCI centres is not necessary when routine ambulance triage systems are 
being developed.  
Since PHT patients have better outcomes compared to spoke patients more centres should 
implement the pre-hospital triage for STEMI patients and use ECG equipment with a 
computerized electrographic algorithm or with telemedicine. It is also important to make 
patients and general practitioners aware of the fact that PHT with ambulance transport has 
better outcomes for STEMI patients instead of self-referring, referring via general practitioners 
or referring via a spoke centre.  
 
Limitations 
Several limitations of this study need to be acknowledged. First, since the project was not 
randomized and dispersed over more than ten years (the percentage of PHT patients 
increased from 6.0% in 1998, 51.6% in 2004 to 68.7% in 2008), consequently the risk of 
unknown confounders exists. Some selection of patients has occurred. PHT patients were 
older and more often lived closer to the PCI centre. During the PHT project, more remote 
ambulance services started participating, while at the beginning these patients all were 
transported via a spoke centre. 
Second, we did not investigate the effect of fibrinolytics for patients living at great distance. 
Therefore, we can not state that pre-hospital diagnosis is the best way to treat all STEMI 
patients living at a great distance, however in our population PHT patients have better 
outcomes when living at >38 km from a PCI centre compared to patients referred via a spoke 
centre.  
Third, we have no exact numbers of patients who were self-referred or came in by ambulance 
at the spoke centre. Most patients came in by ambulance at the spoke centre, however these 
ambulances were not operational with ECG equipment and the EMS personnel was not trained 
to make STEMI diagnosis. Subsequently, diagnosis was made in the spoke hospital, however 
first medical contact took place in the ambulance.  
Fourth, information of the time of first medical contact is lacking. We expect these times to be 
the same in both groups, however we do not have solid evidence.  
Fifth, although peak CK has been shown to be a reliable parameter for the estimation of 
infarct size, data on the area under the CK release curve are lacking.  
Sixth, we have used the postal codes of patient’s residence to calculate the distance to the 
PCI centre, since the exact location of the place where the patient was picked up by an 
ambulance was not available.  
Finally, more research has to be performed to the favour of PHT for patients living at a long 
distance from the PCI centre, so more understanding and verification of this improvement can 
be achieved.  
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 Conclusion 
In conclusion, PHT in the ambulance with immediate transportation to the nearest PCI centre 
is associated with a significantly shorter time to treatment, reduced infarct size and better 
angiographic and clinical outcome when compared to referral via a nearby spoke centre. This 
beneficial effect is more apparent with longer distance from the patient’s residence to the PCI 
centre. PHT also significantly increased the percentage of patients that fall within the time 
window in which pPCI is the preferred treatment according to the AHA/ACC and ESC 
guidelines. Therefore, PHT may reduce transportation delays in patients who live at a greater 
distance from the PCI centre.  
36 37
 REFERENCES 
 
[1] Keeley EC, Hillis LD. Primary PCI for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 
2007;356:47-54. 
[2] Boersma E. The Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 Trialists’ Collaborative 
Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary 
percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. 
Eur Heart J 2006;27:779-88.  
[3] De Luca G, Suryapranata H, Ottervanger JP et al. Time delay to treatment and mortality in primary 
angioplasty for acute myocardial infarction. Every minute of delay counts. Circulation 2004;109:1223-5.  
[4] Dalby M, Bouzamondo A, Lechat P et al. Transfer for Primary Angioplasty Versus Immediate 
Thrombolysis in Acute Myocardial Infarction. A meta-analysis. Circulation 2003;108:1809-14.  
[5] Henry TD, Unger BT, Sharkey SW et al. Design of a standardized system for transfer of patients with 
ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J 2005;150:373-84. 
[6] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for 
acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20. 
[7] Andersen HR, Nielsen TT, Rasmussen K et al. A Comparison of Coronary Angioplasty with Fibrinolytic 
Therapy in Acute Myocardial Infarction. N Eng J Med 2003;349:733-42. 
[8] ACC/AHA. 2007 focussed update of the ACC/AHA 2004 guidelines for the management of patients 
with ST elevated myocardial infarction. JACC 2008;51:210-247. 
[9] The Task Force on the management of ST-segment elevation acute myocardial infarction of the 
European Society of Cardiology: Task force members. Management of acute myocardial infarction in 
patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-2945. 
[10] Pinto DS, Kirtane AJ, Nallamothu BK et al. Hospital delays in reperfusion for ST-elevation myocardial 
infarction: implications when selecting a reperfusion strategy. Circulation 2006;114:2019-25. 
[11] Nallamothu BK, Bates ER, Herrin J et al. Times to treatment in transfer patients undergoing primary 
percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction 
(NRMI)-3/4 analysis. Circulation 2005;111:761–7. 
[12] Terkselsen CJ, Lassen JF, Nørgaard BJ et al. Reduction of treatment delay in patients with ST-
elevated myocardial infarction: impact of pre hospital diagnosis and direct referral to primary coronary 
intervention. Eur Heart J 2005;26:770-7. 
[13] Terkelsen CJ, Nørgaard BJ, Lassen JF et al. Prehospital evaluation in ST-elevation myocardial 
infarction patients treated with primary percutaneous coronary intervention. J of Electrocard 
2005;38:187-92. 
[14] Clemmensen P, Sejersten M, Sillesen M et al. Diversion of ST-elevation myocardial infarction 
patients for primary angioplasty based on wireless prehospital 12-lead electrocardiographic transmission 
directly to the cardiologist’s handheld computer: a progress report. J of Electrocard 2005;38:194-8. 
[15] Pedersen SH, Galatius SG, Hanse PR et al. Field triage reduces treatment delay and improves long-
term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with 
primary percutaneous coronary intervention. J Am Coll Card 2009;54:2296-302 
[16] O’Riordan M. Should patients go directly to a PCI-capable hospital? Two studies, different results. 
Paper presented at: Transcatheter Cardiovascular Therapeutics; September 23, 2009, San Fransico, CA. 
[17] Van ‘t Hof AWJ, Liem A, de Boer MJ et al. Clinical value of 12-lead electrocardiogram after 
successful reperfusion therapy for acute myocardial infarction. The Lancet 1997;350:615-9. 
37
2
 [18] Nienhuis MB, Ottervanger JP, de Boer MJ et al. Prognostic importance of creatin kinase and creatin 
kinase-MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am 
Heart J 2008;155:673-9. 
[19] Van ‘t Hof AWJ, Rasoul S, Wetering H et al. Feasibility and benefit of prehospital diagnosis, triage, 
and therapy by paramedics only in patients who are candidates for primary angioplasty for acute 
myocardial infarction. Am Heart J 2006;151:1255.e1-5 
[20] Zijlstra F, Patel A, Jones M et al. Clinical characteristics and outcome of patients with early (<2h), 
intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic 
therapy for acute myocardial infarction. Eur Heart J 2002;23:550-7.  
[21] Le May MR, Derek YS, Dionne R et al. A citywide protocol for primary PCI in ST-segment elevated 
myocardial infarction. N Eng J Med 2008;358:231-40. 
[22] Wei L, Lang CC, Sullivan FM et al. Impact on mortality following first acute myocardial infarction of 
distance between home and hospital: cohort study. Heart 2008;94:1141-6. 
[23] Peels HO, Swart de H, van der Ploeg T et al. Percutaneous coronary intervention with off-site 
cardiac surgery backup for acute myocardial infarction as a strategy to reduce door-to-balloon time. Am J 
Card 2007;100:1353-8. 
[24] de Boer MJ, Bronzwaer JGF, Boers M. Percutaneous coronary intervention with off-site cardiac 
surgical backup. Am J Card 2008;101:1522. 
38 39
  
 
 
 
 
CHAPTER 3 
 
FIELD TRIAGE IN THE AMBULANCE VERSUS REFERRAL VIA NON-
PERCUTANEOUS CORONARY INTERVENTION CENTRE IN ST-
ELEVATION MYOCARDIAL INFARCTION PATIENTS UNDERGOING 
PRIMARY PERCUTANEOUS CORONARY INTERVENTION: A 
SYSTEMATIC REVIEW 
 
 
 
 
S. Postma 
E. Kolkman 
S.M. Rubinstein 
E.P. Jansma 
G. De Luca 
H. Suryapranata 
A.W.J. Van ‘t Hof 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted 
39
3
 ABSTRACT 
 
AIMS 
To determine whether direct ambulance transport of ST-elevation myocardial infarction 
(STEMI) patients to a percutaneous coronary intervention (PCI) hospital (field triage) leads to 
a lower 30-day mortality compared to transport via a referral non-PCI hospital (referral via a 
spoke center) in STEMI patients.  
 
METHODS AND RESULTS  
We performed a systematic review of interventions. An experienced librarian searched in 
PubMed, EMBASE.com and The Cochrane Library (via Wiley) from January 1980 to February 
2013. Studies that examined field triage and/or referral via a spoke center in STEMI patients 
treated with primary or facilitated PCI were included. Two authors independently conducted 
the study selection and data extraction. Multivariable frequency weighted logistic regression 
analysis was performed to assess the effect of the type of transfer on the outcome measures. 
We identified 14 RCTs, including 20 transfer groups and 4474 participants. Thirty-day 
mortality was lower in patients who underwent field triage (3.0%; 95% CI 2.2-4.2) compared 
to patients who were referred via a spoke center (4.7%; 95% CI 4.0-5.5). In multivariable 
frequency weighted logistic regression analysis, field triage was independently associated with 
a lower incidence of 30-day mortality (OR, 0.58; 95% CI 0.37-0.89). 
 
CONLUSION  
Field triage compared to referral via a spoke center leads to a lower 30-day mortality in 
STEMI patients. Therefore, direct ambulance transport to a PCI hospital should become the 
transfer type for STEMI patients.  
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 INTRODUCTION 
It is well known that rapid restoration of coronary blood flow in patients with ST-elevation 
myocardial infarction (STEMI) is crucial [1] to limit myocardial damage [2-3]. There are two 
established therapeutic strategies to achieve this: fibrinolytic therapy and primary 
percutaneous coronary intervention (PCI). The latter is considered more effective [2, 4-7]. 
However, there is still debate about the time interval during which primary PCI can be 
recommended. One of the possibilities to shorten delays and maximise the number of patients 
eligible for primary PCI, is to transport STEMI patients directly to a PCI hospital after pre-
hospital triage and diagnosis in which case treatment is started immediately in the ambulance 
(field triage). However, it is controversial whether such a strategy, when routinely applied, 
translates in better clinical outcomes. Several observational cohort studies have shown that 
this strategy can significantly reduce ischemic times and some demonstrated that it leads to 
improved outcome compared to patients being referred to a referral non-PCI hospital first and 
later to a PCI hospital (referral via a spoke center) [8-14]. At present, no randomized clinical 
trials (RCT) have been performed, in which patients were randomized to field triage versus 
referral via a spoke center. Therefore, in our study a comparison has been made between 
transfer groups (field triage versus referral via a spoke center) of RCTs in which 30-day 
mortality was assessed. 
 
METHODS 
Criteria for considering studies for this review 
Types of studies 
RCTs, pseudo RCTs (RCTs with alternate method of allocation) and controlled clinical trials 
were included. 
 
Types of participants 
Studies that examined the following population were included: >18 years, chest pain in the 
last 24 hours, ECG changes (ST-segment depression and/or ST-segment elevation) and 
underwent primary PCI or facilitated PCI (early pharmacologic reperfusion therapy followed by 
PCI). Furthermore, the type of transfer to the PCI hospital (field triage and/or referral via a 
spoke center) needed to be elucidated and 30-day mortality needed to be one of the outcome 
measures.  
The exclusion criteria were: self-referring patients admitted to the PCI-hospital, in case 
reperfusion therapy (primary PCI/facilitated PCI and/or fibrinolytic therapy) was presented as 
combined data and the effect of the different therapies could not be discerned. Self-referring 
patients were excluded because these patients did not receive pre-hospital triage, diagnosis 
and treatment, and were not transferred with an ambulance to a PCI center. 
 
Types of interventions 
The interventions who were examined in this review included field triage versus referral via a 
spoke center.  
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 Type of outcome measure 
The primary endpoint of this study was all-cause mortality at 30 days. 
 
Search methods for identification of studies 
Electronic searches 
To identify all relevant publications an experienced librarian (EPJ) performed systematic 
searches (search date: February 2, 2013) in the bibliographic databases PubMed, 
EMBASE.com and The Cochrane Library (via Wiley) from January 1980-February 2013. Search 
terms included controlled terms from MeSH in PubMed, EMtree in EMBASE.com as well as free 
text terms. Free text terms were only used in The Cochrane library. Search terms expressing 
‘ST-elevation myocardial infarction patients’ were used in combination with search terms 
comprising ‘primary percutaneous coronary intervention’ and terms for ‘field triage or referral 
via a spoke center’. The search strategy is available upon request from the primary author. 
 
Searching other resources 
Proceedings from the ESC (www.escardio.org), the ACC (www.acc.org), the AHA 
(www.aha.org), the EUROPCR (www.europcr.com) and the TCT (www.TCTconference.com) 
were examined over the last five years. Also other systematic reviews with similarly research 
questions were checked. The references of relevant articles were checked manually. 
Furthermore, experts in the field were contacted (HS, AWJvtH). 
 
Data collection and analysis 
All steps of the data collection and data analysis were conducted by two reviewers 
independent of one another (SP and EK). This included the identification of studies and data 
extraction. All disagreements were resolved through consensus. 
 
Selection of studies 
Titles and abstracts from the search results were screened and full texts of potentially 
relevant studies were read and independently assessed for inclusion. Only full text articles 
were included and the studies needed to be published in Dutch, English or German. 
Studies were selected if they met the aforementioned in- and exclusion criteria. In case not all 
transfer groups of the selected study met the criteria of our study, only the transfer group(s) 
was/were included which met all criteria. Consequently, only of these transfer groups data 
was extracted. The most common reason for exclusion of a transfer group was treatment with 
fibrinolytic therapy. 
 
Data extraction and management 
A standardized form was used to extract the qualitative data. The following data were 
extracted: source, eligibility, methods, participants, outcomes, results, interventions and 
miscellaneous. The methods included the assessed intervention of the selected study. 
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 Statistical analysis 
Continuous data were expressed as mean ± standard deviation (SD) or median and 
interquartile range (IQR) when considered skewed. Dichotomous data were presented as 
percentage. 
The proportions, percentages and absolute numbers of the primary endpoint were calculated 
for each transfer group (field triage and referral via a spoke center) separately and all groups 
combined. The summary effect was calculated by the addition of the absolute numbers 
of patients that experienced the outcome divided by the total number of patients within the 
transfer group. Corresponding 95% confidence intervals (CIs) for single proportions were 
determined according to the Wilson method, which uses asymptotic variance and no 
continuity correction [15]. The number needed to treat (NNT) was calculated for the outcome 
measure 30-day mortality. 
Modelling. In the univariable analysis, the transfer effect of field triage compared to referral 
via a spoke center was calculated using a frequency weighted logistic regression analysis. This 
analysis has the opportunity to give more weight to studies with a high inclusion number and 
less weight to studies with a low inclusion number. To perform this analysis, the two transfer 
groups (field triage and referral via a spoke center) were both split into two separate groups. 
The first group consisted of the patients that did experienced the outcome, as defined by the 
number of patients presented in the individual studies. The second group consisted of the 
patients that did not experienced the outcome. Subsequently a logistic regression analysis 
was performed in which the outcome variable was weighted for the numbers of patients in the 
transfer groups, since the number of patients differed between the transfer groups. 
To correct for differences in baseline characteristics between the two transfer groups a 
multivariable frequency weighted logistic regression analysis was performed. The variables 
diabetes mellitus and year of publication were included. 
All probability values were 2 tailed, with statistical significance set at 0.05. Analyses were 
performed with SPSS version 20.0 (SPSS Inc, Chicago, Ill) and STATA version 12.0 (STATA 
Corp, College Station, Tex). Figures were constructed with GraphPad Prism 5 and Review 
Manager 5. 
 
Dealing with missing data 
It was expected that the amount of missing data was low, since all included studies were 
performed in the last two decennia. In case of missing data we have contacted the authors of 
the primary studies. No data were imputed, since we had no individual patient data. 
It should be noted that after personal contact with the investigators of several trials [16-20], 
we have received and used several unpublished data concerning baseline characteristics [16-
17] and 30 day mortality [16, 18]. The data of the Assent 4-PCI study were not published 
previously per transfer group and per type of reperfusion therapy (pPCI and facilitated PCI) 
[16]. 
43
3
 The authors are fully responsible for the design and conduct of this study, all study analyses 
and drafting and editing of the paper. 
 
RESULTS 
Results of the search and included studies 
In total, 14 RCTs were selected in the systematic review (Figure 1) [6, 16-28]. Twenty 
transfer groups comprising 4474 participants were extracted. Study sample sizes ranged from 
ten to 988 in the studies (median, IQR: 148 (80-492)) and from five to 988 patients in the 
included transfer groups (median, IQR: 166 (58-293)). 
 
Figure 1. Study flow diagram. Summary of selection process. 
 
Type of transfer and study population 
In four studies patients underwent field triage [17-18, 27-28] and in eight studies patients 
were referred via a spoke center [6, 20-26]. Two studies included both field triage and 
referral via a spoke center [16, 19]. Nevertheless in these studies patients were not 
randomized to field triage versus referral via a spoke center, however a post hoc analysis was 
performed. 
Of the 20 transfer groups, in nine transfer groups patients underwent field triage (n=1151) 
and in 11 transfer groups patients underwent referral via a spoke center (n=3307). 
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 An overview of the baseline characteristics is demonstrated in Table 1 for patients treated 
with field triage and in Table 2 for patients treated with referral via a spoke center 
respectively. The type of reperfusion therapy, the prescribed anti-platelet agents as well as 
time delays are also shown. Time from symptom onset to diagnosis and time from symptom 
onset to reperfusion therapy were demonstrated as mean ± SD or as median and IQR. 
Therefore, no overall measurement effect could be examined for the two time intervals. 
 
Effects of interventions 
30-day mortality was lower in patients who underwent field triage (3.0%; 95% CI 2.2-4.2) 
compared to patients who were referred via a spoke center (4.7%; 95% CI 4.0-5.5) (Figure 
2A and 2B). Field triage was associated with a reduced risk on 30-day mortality (NNT=59). 
The unadjusted effect of field triage on 30-day mortality was lower (OR: 0.64, 95% CI 0.44-
0.93) compared to referral via a spoke center. In multivariable frequency weighted logistic 
regression analysis this effect was confirmed (OR: 0.58; 95% CI 0.37-0.89). 
 
Figure 2. Forrest-tree plot of primary and secondary end point. 
Percentages of 30-day mortality with corresponding 95% CIs for single proportions are shown for the field 
transfer group (A) and for the referral via a spoke center group (B).  
CI: confidential interval, Fac: facilitated, pPCI: primary percutaneous coronary intervention, PCI: percutaneous 
coronary intervention. 
* The CI of the SONOLYSIS (treatment) and SONOLYSIS (control) group was both groups 0.00-0.43.  
 
DISCUSSION 
Summary of main results 
To our knowledge this is the largest performed systematic review which assessed the effect of 
field triage versus referral via a spoke center on 30-day mortality. The most important finding 
of our study is that field triage leads to a lower 30-day mortality. 
 
Agreements and disagreements with other studies and reviews 
The fact that patients treated with field triage have a lower 30-day mortality is in line with 
most of the performed studies published so far [8-14]. However, in the post-hoc analysis of 
the On-TIME study no beneficial effect of field triage compared to referral via a spoke center 
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 was demonstrated [19]. This might be explained by the fact that in this trial the amount of 
included patients was not sufficient to reach significance. In the post-hoc analysis of the 
Assent 4-PCI study also no significant difference was found between the two transfer groups, 
although mortality was assessed at 90 days instead of 30 days [16]. Furthermore, there were 
some studies who demonstrated no need to transfer patients for pPCI from a non-PCI centre, 
however in these studies transfer patients were compared to patients already presenting at a 
tertiary PCI center without the need for transfer [21-22, 29-30]. 
Our results are in contrast with the publication of Brooks et al., in which the conclusion of the 
systematic review and meta-analysis was that there is insufficient evidence to support the 
effectiveness of field triage compared to referral via a spoke center in STEMI patients 
concerning mortality [31]. However, they applied different criteria for considering studies: 
besides RCTs they also included prospective observational cohort studies and they did not 
include studies with one transfer arm of interest. Furthermore, their endpoint was a 
composite of in-hospital and 30-day mortality. Therefore, only one study was included in both 
reviews. 
 
Potential biases in the review process 
We have not chosen to include prospective observational cohort studies besides RCTs, pseudo 
RCTs and controlled clinical trials, since these studies are biased in multiple ways. After all in 
our study only RCTs were included, because no pseudo RCTs and controlled clinical trials were 
performed. 
 
Limitations 
Several limitations of our systematic review should be noted. Firstly, since in this review 
transfer groups of studies were compared instead of RCTs, no meta-analysis could be 
performed and the comparison made in our study was non randomized. Considering this 
result, for the future RCTs are warranted. However it is highly unlikely that new RCTs 
investigating this topic will be designed and subsequently approved by an ethical committee, 
because referral via a spoke center is usually coincided with prolonged treatment delays and 
therefore in conflict with the current ESC and AHA/ACC guidelines [32-33]. Hence, our study 
design seems to be the best choice to assess the research question of our study. Secondly, 
only a few variables were included in the weighted multivariable analysis since 20 transfer 
groups were included. The effect of time from symptom onset to diagnosis/randomization and 
time from symptom onset to reperfusion could not be included, because the data from the 
selected studies in this review did not allow for a detailed exploration of the relationship 
between the relative benefit of the type of transfer and the abovementioned time intervals. 
Therefore, we are unable to pronounce upon maximum time delays for the types of transfer. 
Thirdly, because no more than 14 studies were included, sensitivity analyses were not 
performed. 
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 Conclusion 
In conclusion, field triage compared to referral via a spoke center leads to a lower 30-day 
mortality in STEMI patients. Therefore, direct ambulance transport to a PCI hospital should 
become the transfer type for STEMI patients. Future studies should determine the optimal 
timing for field triage versus referral via a spoke center. 
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 ABSTRACT 
 
AIMS 
To evaluate the relation between residential distance and total ischaemic time in patients with 
acute ST-elevation myocardial infarction (STEMI). 
 
METHODS  
STEMI patients were transported to the Isala Hospital Zwolle with the intention to perform 
primary percutaneous coronary intervention PCI (pPCI) from 2004 until 2010 (n=4149). Of 
these, 1424 patients (34 %) were referred via a non-PCI ‘spoke' centre (‘spoke’ patients) and 
2725 patients (66 %) were referred via field triage in the ambulance (ambulance patients). 
 
RESULTS  
A longer residential distance increased median total ischaemic time in ‘spoke’ patients (0–30 
km: 228 min, >30-60 km: 235 min, >60-90 km: 264 min, p<0.001), however not in 
ambulance patients (0–30 km: 179 min, >30-60 km:175 min, >60-90 km: 186 min, 
p=0.225). After multivariable linear regression analysis, in ‘spoke’ patients residential 
distance of >30-60 km compared with 0–30 km was not independently associated with 
ischaemic time; however, a residential distance of >60-90 km (exp (B)=1.11, 95% CI 1.01-
1.12) compared with 0–30 km was independently related with ischaemic time. In ambulance 
patients, residential distance of >30-60 and >60-90 km compared with 0–30 km was not 
independently associated with ischaemic time. 
 
CONCLUSION 
A longer distance from the patient’s residence to a PCI centre was associated with a small but 
significant increase in time to treatment in ‘spoke’ patients, however not in ambulance 
patients. Therefore, referral via field triage in the ambulance did not lead to a significant 
increase in time to treatment, especially at long distances (up to 90 km). 
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 INTRODUCTION 
Strategies to reduce time delays in ST-segment elevated myocardial infarction (STEMI) 
patients are currently of great interest, since shorter time delays improve outcome [1–5]. 
Transportation delay is a time delay which is mainly dependent on the type of transport, 
mode of referral, geographical area, weather conditions, traffic and distance. In urban areas, 
ambulance transport is the transport of choice and in rural areas air transport usually 
facilitates the transfer of STEMI patients. Previous studies have shown that optimising 
logistics by field triage in the ambulance can help to reduce time to treatment and improve 
outcomes compared to referral via a non-percutaneous coronary intervention (PCI) spoke 
centre (peripheral centre) [5–12]. Only a few published data exist on the effect of 
geographical area [8, 13–16], weather conditions [16], traffic [16] and distance [5, 16–19] 
on time to treatment.  
In the Netherlands, distance to a PCI centre (hub centre: specialised central interventional 
centre) was one of the reasons to expand primary PCI to more hospitals, including those 
without on-site cardiac surgery. It was expected that with more PCI centres transportation 
delay might decrease and clinical outcomes might improve. However, recently Concannon et 
al. demonstrated that introducing new PCI centres did not help patients gain access to timely 
PCI [20]. Therefore, we have investigated the relation between residential distance and total 
ischaemic time in STEMI patients referred to a large tertiary PCI centre. In addition, the effect 
of residential distance on total ischaemic time was assessed in patients who were referred via 
a non-PCI spoke (spoke) centre and in patients referred via field triage in de ambulance. 
 
METHODS 
Population 
Since the early 1990s, STEMI patients referred to the Isala Hospital Zwolle were treated by 
primary PCI (pPCI). To improve the logistics of STEMI patients, the field triage project was 
initiated. This has gradually been implemented in the region, starting in 1998 until all 
ambulances were part of the field triage project. During the project all consecutive STEMI 
patients who were transported to the PCI centre with the intention to perform pPCI, from 
2004 until 2010, were prospectively registered in a dedicated database. Criteria for the 
diagnosis of STEMI were: 1) history of cardiac symptoms of at least 30 min in the last 12 h or 
between 12 and 24 h if they had persistent symptoms with evidence of ongoing ischaemia; 2) 
elevated levels of creatine kinase (CK) or creatine kinase-MB (CK-MB) and 3) concurrent 
electrocardiogram (ECG) changes: ST-segment elevation of >0.1 mV in at least two adjacent 
electrocardiogram leads [21]. 
The residential distance to the nearest PCI centre via the motorway was computerised using 
the postal codes of the patient’s residence and the PCI centre. Subsequently three groups 
were formed according to distance: 1) 0–30 km, 2) >30-60 km and 3) >60-90 km. 
Furthermore, a subdivision by type of triage was performed. Patients were transferred via a 
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 referral spoke centre in the network (spoke group) or via field triage in the ambulance 
(ambulance group). 
Patients were excluded if the distance from the patient’s residence to the PCI centre could not 
be assessed or was >90 km (outer boundary of referring area). 
 
Triage for pPCI 
We hypothesised that the effect of distance on outcome might be different for spoke patients 
versus ambulance patients, as referral logistics are different between the two groups. Spoke 
patients are transported twice: the first time to bring the patient from their residence to the 
nearest spoke centre and a second time to bring the patient to the PCI centre after diagnosis 
of myocardial infarction in the spoke centre. Conversely, ambulance patients are transported 
only once via the shortest and fastest possible way and immediately after myocardial 
infarction diagnosis at the patient’s residence. 
Spoke group: If the ambulance was not equipped with field triage equipment, the ambulance 
went to the nearest spoke centre where diagnosis and triage was performed. If the ECG 
performed upon arrival was diagnostic for STEMI, patients were transported to the 
catheterisation laboratory of the PCI centre as soon as possible, preferably by using the same 
ambulance. 
Ambulance group: The algorithm of field triage has been described previously [17]. In brief, 
after patients had dialled the emergency number, they were triaged in the ambulance. An 
ECG was performed by highly trained paramedics followed by interpretation by the 
computerised algorithm. If a diagnosis of STEMI was made, the ambulance went straight to 
the catheterisation laboratory of the PCI centre, bypassing the emergency departments of 
nearby spoke centres.  
Walk-ins at the PCI centre were excluded since they did not receive field triage. 
 
pPCI procedure 
In both situations, the staff of the catheterisation laboratory of the PCI centre was pre-
informed about the estimated time of arrival of the patient and was activated well before the 
arrival of the patient. If the staff lived more than 30 min away from the PCI centre, they had 
to stay in the PCI centre when on call. All patients were treated pre-hospital with an 
intravenous bolus of 5000 IU of unfractionated heparin and 500 mg aspirin intravenously. 
During the study period the administration of clopidogrel on top of aspirin and heparin as pre-
hospital treatment was implemented at 1 July 2006. The administration of GP IIb/IIIa 
blockers in the pre-hospital phase was left at the discretion of the referring physicians. 
 
Time intervals 
Four different time intervals were evaluated: 1) Time from symptom onset to infarct diagnosis 
(time of diagnostic ECG) either in the ambulance or at a spoke centre (symptom onset to 
diagnosis); 2) Time from diagnosis till arrival at the PCI centre (diagnosis to door PCI); 3) 
58 59
 Time from arrival at the PCI centre to balloon inflation (door to balloon) and 4) Total 
ischaemic time defined as the time from symptom onset to balloon inflation. 
Patients were excluded if the total ischaemic time could not be assessed. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 20.0. Continuous data were expressed as mean 
± SD or median and interquartile range. Categorical data were presented as percentages. A 
Kruskal-Wallis test was used for continuous data, since they were non-Gaussian distributed. A 
Pearson’s Chi-square test was used for categorical data. The relationship between total 
ischaemic time and residential distance for each patient was assessed using Spearman’s 
correlation. Linear regression analysis was performed to estimate the effect of residential 
distance on total ischaemic time. To assess whether the mode of referral might interfere with 
the relationship between residential distance and total ischaemic time, interaction testing was 
performed. For the regression analysis and the interaction testing total ischaemic time was 
log transformed, since this time interval was non-Gaussian distributed. 
All above-described statistical tests were two-sided. In all statistical analyses p values <0.05 
were considered to be statistically significant. 
The study was conducted according to the principles of the Declaration of Helsinki and the 
protocol was approved by the local institutional review board. No extramural funding was 
used to support this work. The authors are solely responsible for the design and conduct of 
this study, all study analyses and drafting and editing of the paper. 
 
RESULTS 
From 2004 until 2010, 5285 patients were referred to our hospital with the intention to 
perform pPCI. A total of 349 patients (6.6%) were walk-ins at the PCI centre, in 184 patients 
the residential distance could not be assessed (3.5%) and 603 patients (11.4%) were 
excluded because the total ischaemic time could not be assessed. 
Of the remaining 4149 patients, 1424 patients (34 %) were referred via a spoke centre and 
2725 (66%) via field triage in the ambulance. Figure 1a and b illustrate the distance from the 
patient’s residence to the PCI centre for the spoke group and the ambulance group on a map 
of the Netherlands. Spoke patients mainly lived between 30–90 km away from the PCI centre, 
while ambulance patients mostly lived within a residential distance of 0–60 km. 
There was a significant interaction effect between residential distance and type of triage on 
total ischaemic time (p=0.038). Therefore, the results are presented separately for the two 
groups. 
 
Spoke group 
The baseline characteristics of spoke patients are described in Table 1. The presence of Killip 
class >1 and incidence of previous CABG decreased with distance from patient’s residence to 
the PCI centre. The correlation between residential distance and total ischaemic time was 
59
4
weak although significant (r=0.078, p=0.003). Furthermore, median total ischaemic time 
increased with distance as well as the other described time intervals (Table 2 and Figure 1A). 
After multivariable linear regression analysis residential distance of >30-60 km (exp 
(B)=0.98, 95% CI 0.90-1.06) compared with 0–30 km was not independently associated with 
ischaemic time, however a residential distance of >60-90 km (exp (B)=1.11, 95% CI 1.01-
1.12) compared with 0–30 km was independently related with ischaemic time. 
 
Ambulance group 
The baseline characteristics of ambulance patients are described in Table 1. The correlation 
between residential distance and total ischaemic time was not significant (r=0.017, p=0.382). 
The time from diagnosis to door PCI increased (p<0.001) and the door to balloon time 
decreased (p<0.001) (Table 2 and Figure 1B). After multivariable linear regression analysis a 
residential distance of >30-60 km (exp (B)=1.00, 95 % CI 0.97-1.04) and of >60-90 km (exp 
(B)=1.06, 95% CI 0.99-1.13) compared with 0–30 km were not independently related to 
ischaemic time. 
 
A                      B 
Figure. 1 Distribution of residential distance and total ischaemic time.  
Above the distance from the patient’s residence to the PCI centre is illustrated on a map of the Netherlands for 
the spoke group (A) and the ambulance group (B). Black dot: Isala Hospital Zwolle, light grey dots: patients 
living 0–30 km from the PCI centre, grey dots: patients living >30-60 km from the PCI centre, dark grey dots: 
patients living >60-90 km from the PCI centre. Below the total ischaemic time is shown for the spoke group (A) 
and the ambulance group (B) for patients living 0–30 km, >30-60 km and >60-90 km from a PCI centre.  
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 DISCUSSION 
Our study is the largest of its kind demonstrating that living further away from a PCI centre 
increases time to treatment in patients referred via a spoke centre, but to a lesser extent in 
patients who were immediately transported after field triage in the ambulance. Overall the 
increase in median total ischaemic time with longer residential distance was modest (30–90 
km: 36 min (spoke) vs. 7 min (ambulance)). This limited effect of residential distance on total 
ischaemic time can partly be explained by the reduced door to balloon time with longer 
residential distance. A longer transportation delay gives the opportunity to prepare the cath-
lab for PCI, after a call from the ambulance or spoke centre. These findings imply that a 
substantial increase in residential distance can be covered with only a modest increase in 
transportation time and suggests that prolonged transportation distances have a limited effect 
on outcome, when other components of the total ischaemic time are optimally organised. This 
was clearly found when patients were diagnosed and immediately transported after 
prehospital triage in the ambulance: for 30–60 km residential distance from the PCI centre 
transportation took 74 min (median) for a spoke patient as compared with 53 min (median) 
for an ambulance patient (Table 2). In this regard it should be emphasised that residential 
distance as mentioned in the study is calculated as the shortest distance by motorway from 
the patient’s residence to the PCI centre. Ambulance-triaged patients were transported via 
this shortest distance whereas spoke patients travelled longer distances. Firstly, on the way to 
the spoke centre and secondly, on the way from the spoke centre to the PCI centre, 
consequently resulting in a longer time to diagnosis and a long inter-hospital transportation 
time.  
Until now, only few data are available on the relation between residential distance and total 
ischaemic time. Recently we showed that field triage in the ambulance may reduce the 
negative effect of living at a longer distance from a PCI centre [5]. Beri et al. have 
demonstrated that longer distances did not result in any significant transfer delay [22]. 
However, they did not investigate the effect of short versus long distance, but the effect of 
pPCI versus fibrinolytic therapy at long distance. 
Besides referring patients directly after field triage in the ambulance to a PCI centre, 
expansion of primary PCIs to more hospitals is also a widely discussed option to improve 
treatment delay [20, 23]. 
We believe expansion of PCI centres may play less of a role in the overall improvement of 
timely treatment of STEMI patients, since our results demonstrate that residential distance is 
only weakly associated with total ischaemic time if patients are transferred via field triage in 
the ambulance. Furthermore, the number, availability and expertise of the interventional 
cardiologists plays also an important role in providing timely access to PCI as well as the 
expertise of ambulance personnel. In addition, in the future more attention is needed for 
changes in PCI capacity and the effects of these changes on outcome measures as well as on 
the selection of high-risk patients for transfer. 
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 Limitations 
Firstly, the postal code of the patients’ residence was used as a proxy for the place where the 
ambulance picked up the patient. Information on the exact distance between the patient’s 
residence and the place where the ambulance picked up the patient was not available. 
However, a random sample of 716 cases revealed that >80 % of the patients were picked up 
<5 km from their residence. Secondly, since the project was not randomised and was spread 
over more than 10 years, the risk of unknown confounders exists. Thirdly and perhaps the 
most important limitation is the fact that our study was performed in a small country with a 
flat landscape where ambulance triage for STEMI patients is optimised, where distances 
between the patient’s residence and PCI centres are surmountable to treat most patients 
according to the ACC/AHA and ESC guidelines and where traffic and weather conditions are no 
major issue. More research is needed to investigate whether comparable results can be 
achieved in other areas of the world. 
 
Conclusions 
A longer distance from the patient’s residence to a PCI centre was associated with a small but 
significant increase in time to treatment in patients referred via a non-PCI spoke centre, 
although this association was weak. In patients who were referred via field triage in the 
ambulance there was no significant association between residential distance and time to 
treatment. Therefore, referral via field triage in the ambulance did not lead to a significant 
increase in time to treatment, especially at long distances (up to 90 km). 
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 ABSTRACT 
 
AIMS 
To evaluate the relation between system delay and 30-day and long term mortality in patients 
with anterior versus non-anterior ST-elevation myocardial infarction (STEMI). 
 
METHODS 
We conducted a prospective observational cohort study. STEMI patients who were transported 
to the Isala hospital Zwolle and underwent primary percutaneous coronary intervention (pPCI) 
from 2005 until 2010 were included. These patients were divided in quartiles of system delay 
(time from first medical contact until reperfusion therapy): Q1-Q4. 
 
RESULTS 
In total, 3041 patients were included in our study. Forty one percent (n=1253) of the patients 
had an anterior myocardial infarction (MI) and 59% percent of the patients (n=1788) had a 
non-anterior MI. Only in patients with an anterior MI, prolonged system delay was associated 
with a higher mortality (30-day Q1: 2.6%, Q2: 3.1%, Q3: 6.8%, Q4: 7.4%, p=0.001; long 
term Q1: 12.8%, Q2: 13.7%, Q3: 24.1%, Q4: 22.6%, p<0.001). After multivariate 
adjustment prolonged system delay was associated with a higher 30-day and long-term 
mortality in anterior MI patients (30 day Q2: HR 1.18 95% CI (0.46-3.00), Q3: HR 2.45 95% 
CI (1.07-5.63), Q4:HR 2.25 95% CI (0.97-5.25)); long term Q2: HR 1.09 95% CI (0.71-
1.68), Q3: HR 1.68 95% CI (1.13-2.49), Q4: HR 1.55 95% CI (1.03-2.33)), but not in 
patients with a non-anterior MI. 
 
CONCLUSIONS 
Prolonged system delay significantly increased short as well as long term mortality in patients 
with an anterior MI. This effect was not demonstrated in patients with a non-anterior MI. 
Therefore it is of the greatest importance to minimize system delay in patients who present 
with an anterior MI. 
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 INTRODUCTION 
As stated in the guidelines of the American College of Cardiology/American Heart Association 
(ACC/AHA) and of the European Society of Cardiology (ESC) it is crucial to perform rapid 
reperfusion therapy in patients with ST-segment elevated myocardial infarction (STEMI) [1-
2], because every minute of delay in these patients affects mortality [3]. Therefore, currently 
time delays like system delay, patient delay, transportation delay, door-in-door-out (DIDO) 
time and door-to-balloon (D2B) time are of great interest in STEMI patients [4-8]. System 
delay, defined as time from first medical contact (FMC, i.e. EMS call) to reperfusion therapy, 
is a relatively new time delay which can be optimized by optimizing the system. As 
demonstrated by Terkelsen et al. system delay was independently associated with mortality 
[4]. Since we hypothesised that this effect would be the most apparent in high risk patients, 
we have investigated the effect of system delay on 30-day and long term mortality in patients 
with an anterior myocardial infarction (MI) versus a non-anterior MI. 
 
METHODS AND ANALYSIS 
Population 
All consecutive STEMI patients who were transported to our percutaneous coronary 
intervention (PCI) centre with the intention to perform pPCI from 2005 until 2010, were 
prospectively registered in a dedicated database. Criteria for the diagnosis of STEMI were: (1) 
history of cardiac symptoms of at least 30 minutes in the last 12 hours or between 12 and 24 
hours if they had persistent symptoms with evidence of ongoing ischemia (2) elevated levels 
of Creatin Kinase or Creatin Kinase-MB and (3) concurrent electrocardiogram changes: ST-
segment elevation of >0.1mV in at least two adjacent electrocardiogram leads [9]. 
Infarct size was calculated as the peak level of Creatin Kinase (peak CK) within 24 hours after 
admission [10]. The municipal registration in the Netherlands was consulted for the mortality 
of all patients in this study. 
The included population was divided in four groups according to the quartiles of system delay 
(Q1, Q2, Q3 and Q4). System delay was defined as the time from FMC, i.e. EMS call to 
reperfusion therapy. Four other time intervals were also evaluated 1. Symptom onset (SO)-
diagnosis: time from SO to indication MI (time diagnostic electrocardiogram (ECG)) either in 
the ambulance or at a spoke centre 2. Diagnosis-Door PCI: time from diagnosis to arrival at 
the PCI centre 3. D2B: time from arrival at the PCI centre to balloon inflation (BI) and 4. Total 
ischemic time: time from SO to BI. 
Patients were excluded if one of the following criteria was met: patients were walk-ins, they 
were not treated by PCI, D2B time was >180 minutes, system delay was unknown or 
mortality could not be retrieved. 
 
pPCI procedure 
The staff of the catheterization laboratory of the PCI centre was pre-informed about the 
estimated time of arrival of the patient and was activated well before the arrival of the 
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 patient. In case the staff lived more than 30 minutes away from the PCI centre, they had to 
stay in the PCI centre while being on-call. All patients were treated pre-hospital with an 
intravenous bolus of 5000 IU of unfractionated heparin and 500 mg aspirin intravenously. 
During the study period the administration of clopidogrel on top of aspirin and heparin as pre-
hospital treatment was implemented at July first 2006. The administration of GPIIBIIIA 
blockers in the pre-hospital phase was left at the discretion of the referring physicians. 
The location of the acute vessel occlusion was determined in this study by the PCI operator. 
Consequently two groups were made according to the location: left anterior descending artery 
(LAD; anterior MI) versus non-LAD (non-anterior MI). 
 
Statistical analysis 
Statistical analysis was performed with SPSS 20.0. Continuous data were expressed as mean 
± SD or median and interquartile range. Categorical data were presented as percentage. A 
Kruskal-Wallis test was used for continuous data, since they were non-Gaussian distributed. A 
Pearson’s Chi-square test was used for categorical data. The continuous variable infarct size 
was converted into a dichotomous variable by dividing the de continuous variable in 
interquartile ranges and defining the interquartile range 0.75-1.00 as large enzymatic infarct 
size (75th percentile). A p for trend was calculated for large enzymatic infarct size, and for 30-
day and long term mortality between the quartiles of system delay. 
To assess whether anterior MI might interfere with the relationship between system delay and 
30-day and long term mortality, interaction testing was performed. 
Logistic regression analyses was performed to estimate the effect of system delay on large 
enzymatic infarct size. Variables included in the models were age, gender, smoking, diabetes 
mellitus (DM), hypertension, hypercholesterolemia, previous MI, previous PCI, previous 
coronary artery bypass grafting (CABG), type of triage, ST deviation on diagnostic ECG and 
the quartiles of system delay. Cox regression analysis was performed to estimate the effect of 
system delay on 30-day and on long-term mortality. Variables included in the models for 30-
day mortality were age, gender, DM, hypertension, type of triage, TIMI risk score and the 
quartiles of system delay. For the Cox regression analysis of long term mortality additionally 
previous MI, previous PCI and previous CABG were added. 
All above described statistical tests were performed two-sided. In all statistical analyses p-
values <0.05 were considered as statistically significant. 
The study was conducted according to the principles of the Declaration of Helsinki and the 
protocol was approved by the local institutional review board. No extramural funding was 
used to support this work. The authors are fully responsible for the design and conduct of this 
study, all study analyses and drafting and editing of the paper. 
 
RESULTS 
From 2005 until 2010, 4655 patients were referred to our hospital with the intention to 
perform pPCI. Three hundred twelve patients (7.7%) were walk-ins at the PCI-centre, 668 
70 71
patients did not undergo PCI (14.3%), in 344 patients the D2B time was >180 minutes 
(7.4%), of 245 patients system delay was unknown (5.3%) and in 45 patients (1.0%) 
mortality could not be retrieved. Of the remaining 3041 patients, forty one percent (n=1253) 
of the patients had an anterior MI and 59% (n=1788) had a non-anterior MI. There was a 
significant interaction effect between anterior infarction and the quartiles of system delay on 
30-day (p=0.048) and on long term mortality (p=0.027). Therefore, the results are presented 
separate for patients with an anterior MI and patients with a non-anterior MI. 
 
Anterior MI 
The baseline characteristics are described in Table 1. Patients with a prolonged system delay 
were older, were less often triaged in the field and had less ST-deviation on the diagnostic 
ECG. Gender, DM and the thrombolysis in myocardial infarction (TIMI) risk score differed 
among the quartiles of system delay. The time intervals are illustrated in Figure 1A. All time 
delays were significantly different between the quartiles of system delay. The median follow-
up time was 5.3 (3.6-6.6) years. System delay was independently associated with a large 
enzymatic infarct size (Q2: OR 1.85 95% CI (1.19-2.86), Q3: OR 1.80 95% CI (1.15-2.81), 
Q4: OR 1.15 95% CI (0.72-1.84)). After Cox regression analysis prolonged system delay was 
independently associated with 30-day mortality (Q2: HR 1.18 95% CI (0.46-3.00), Q3: HR 
2.45 95% CI (1.07-5.63), Q4: HR 2.25 95% CI (0.97-5.25)) and with long term mortality 
(Q2: HR 1.09 95% CI (0.71-1.68), Q3: HR 1.68 95% CI (1.13-2.49), Q4: HR 1.55 95% CI 
(1.03-2.33)) (Figure 2A). 
 
 
Figure 1. Time delays 
The different time intervals are shown for patients with an anterior MI (A) and patients with a non-anterior MI 
(B). IQR: interquartile range, MI: myocardial infarction, min: minutes, PCI: percutaneous coronary 
intervention, SO: symptom onset.  
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Non-anterior MI 
The baseline characteristics are described in Table 1. Patients with prolonged system delay 
more often had a previous CABG, were less often diagnosed in the field and had less ST-
deviation on the diagnostic ECG. There was a difference in previous MI and TIMI risk score 
among the quartiles of system delay. The culprit vessel was in 1231 patients (68.8%) the 
right coronary artery (RCA) and in 425 patients (23.8%) the circumflex artery (CX). The time 
intervals are illustrated in Figure 1B. All time delays were significantly different between the 
quartiles of system delay. The median follow-up time was 5.2 (3.6-6.8) years. System delay 
was not associated with a large enzymatic infarct size (Table 2). After Cox regression analysis 
system delay was not associated with 30-day or with long term mortality (Figure 2B). 
 
A  
B  
Figure 2. Mortality 
Cox regression curves are shown for long term mortality for patients with an anterior MI (A) and patients with a 
non-anterior MI (B). 
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5
 DISCUSSION 
The present study is the first that assesses the effect of system delay on 30-day and long 
term mortality in anterior and non-anterior MI patients separately. Interestingly, our results 
demonstrate that in patients with an anterior MI system delay was significantly associated 
with 30-day and long term mortality. This effect was not apparent in patients with a non-
anterior MI. 
As demonstrated by Terkelsen et al. system delay seems to be the reasonable time delay to 
focus on in nonrandomized studies, since confounding, selection bias, information bias and 
recall bias hamper the other currently discussed time delays. Another advantage of this time 
delay is that this delay can be optimized during the pre-hospital triage as well as during the 
in-hospital triage [4]. 
Highly trained paramedics from several ambulance services transfer their patients to our high 
volume Isala hospital in which over 2000 PCIs are performed yearly. Even though all pre- and 
in hospital strategies and procedures are optimized, the variation between the quartiles of 
system delay differed between 72 min (Q1) versus ≥ 160 min (Q4). A possible explanation for 
the variation in system delay, is the fact that very sick patients are also included in this study 
and these patients have longer delays. As demonstrated, in general the TIMI risk score 
increases with system delay in both patient groups. Furthermore, D2B time increased with 
system delay despite an increase in patient delay (time from SO-diagnosis). The latter might 
be explained by the fact that in patients with the longest system delay (Q4) more often a 
decrease in symptoms was demonstrated after arrival in the PCI hospital. Non-system 
reasons might also account for these findings. Examples of non-system delays include delays 
in providing procedure consent, difficult access, difficulty crossing the culprit lesion and 
patients who have a cardiac arrest requiring intubation before PCI [11]. 
An increase in 30-day and long term mortality was demonstrated with system delay in 
patients with an anterior MI. We anticipated that in these patients also an increase in infarct 
size would be demonstrated since a large amount of myocardium is at risk in these patients 
and hence anterior MI is a strong baseline determinant of infarct size [12]. Furthermore, the 
association between system delay and infarct size has recently been demonstrated by 
Lønborg et al. and Tödt et al [13-14]. In our population however, only an increase in infarct 
size was demonstrated in patients with an anterior MI in the first three quartiles of system 
delay (Q1-Q3). An explanation for this result might be that patients with the longest system 
delays (Q4) had less severe and distinct symptoms and less deviations on the ECG, which has 
consequently lead to a prolonged D2B time. In addition, Lønborg et al. and Tödt et al. used 
magnetic resonance imaging to asses the myocardial area at risk, which was not used in our 
study. 
While prolonged system delay is associated with an increased mortality, especially in patients 
with an anterior MI, it is of the greatest importance to minimize system delay as much as 
possible. Therefore, currently several strategies have been developed to reduce system delay 
and other time delays. Firstly, it is very important that the patients are triaged in the field by 
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 DISCUSSION 
The present study is the first that assesses the effect of system delay on 30-day and long 
term mortality in anterior and non-anterior MI patients separately. Interestingly, our results 
demonstrate that in patients with an anterior MI system delay was significantly associated 
with 30-day and long term mortality. This effect was not apparent in patients with a non-
anterior MI. 
As demonstrated by Terkelsen et al. system delay seems to be the reasonable time delay to 
focus on in nonrandomized studies, since confounding, selection bias, information bias and 
recall bias hamper the other currently discussed time delays. Another advantage of this time 
delay is that this delay can be optimized during the pre-hospital triage as well as during the 
in-hospital triage [4]. 
Highly trained paramedics from several ambulance services transfer their patients to our high 
volume Isala hospital in which over 2000 PCIs are performed yearly. Even though all pre- and 
in hospital strategies and procedures are optimized, the variation between the quartiles of 
system delay differed between 72 min (Q1) versus ≥ 160 min (Q4). A possible explanation for 
the variation in system delay, is the fact that very sick patients are also included in this study 
and these patients have longer delays. As demonstrated, in general the TIMI risk score 
increases with system delay in both patient groups. Furthermore, D2B time increased with 
system delay despite an increase in patient delay (time from SO-diagnosis). The latter might 
be explained by the fact that in patients with the longest system delay (Q4) more often a 
decrease in symptoms was demonstrated after arrival in the PCI hospital. Non-system 
reasons might also account for these findings. Examples of non-system delays include delays 
in providing procedure consent, difficult access, difficulty crossing the culprit lesion and 
patients who have a cardiac arrest requiring intubation before PCI [11]. 
An increase in 30-day and long term mortality was demonstrated with system delay in 
patients with an anterior MI. We anticipated that in these patients also an increase in infarct 
size would be demonstrated since a large amount of myocardium is at risk in these patients 
and hence anterior MI is a strong baseline determinant of infarct size [12]. Furthermore, the 
association between system delay and infarct size has recently been demonstrated by 
Lønborg et al. and Tödt et al [13-14]. In our population however, only an increase in infarct 
size was demonstrated in patients with an anterior MI in the first three quartiles of system 
delay (Q1-Q3). An explanation for this result might be that patients with the longest system 
delays (Q4) had less severe and distinct symptoms and less deviations on the ECG, which has 
consequently lead to a prolonged D2B time. In addition, Lønborg et al. and Tödt et al. used 
magnetic resonance imaging to asses the myocardial area at risk, which was not used in our 
study. 
While prolonged system delay is associated with an increased mortality, especially in patients 
with an anterior MI, it is of the greatest importance to minimize system delay as much as 
possible. Therefore, currently several strategies have been developed to reduce system delay 
and other time delays. Firstly, it is very important that the patients are triaged in the field by 
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5
 an ambulance and are transferred straight to the cathlab of the PCI centre, bypassing the 
non-PCI centres and the emergency department of the PCI centre [15]. In our population the 
benefit of this implemented strategy was obvious, i.e. it was demonstrated that the amount of 
patients triaged in the field by an ambulance in Q1 was almost twice compared to the amount 
in Q4. Secondly, detailed identification of the time delays is essential so understanding can be 
gained. Thirdly, collaborative discussions and feedback to staff involved in the care of STEMI 
patients can make sure that the time delays can be optimized as much as possible. Points of 
discussion and feedback at present are 1) ECG recording by the highly trained paramedics in 
the ambulance, 2) central judgement of an ECG in the hospital, 3) timely preparation of 
cathlab and 4) pre- and in-hospital logistics [16]. 
 
Limitations 
Firstly, the time of diagnosis was used together with the time of reperfusion therapy as a 
proxy for system delay. Information on the time of FMC was not available for all patients. 
However, a random sample of 94 cases revealed that in 83% of these patients the difference 
between FMC (i.e. EMS call) and diagnosis was ≤ 10 minutes. Secondly, since the project was 
not randomized and dispersed over several years, consequently the risk of unknown 
confounders exists. Thirdly, the level of peak CK within 24 hrs was used as surrogate 
parameter for infarct size. 
 
CONCLUSIONS 
Prolonged system delay significantly increased short as well as long term mortality in patients 
with an anterior MI. This effect was not demonstrated in patients with a non-anterior MI. 
Therefore it is of the greatest importance to minimize system delay in patients who present 
with an anterior MI. 
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 ABSTRACT 
 
BACKGROUND 
Pre-hospital infarct diagnosis gives the opportunity to start anti-platelet and anti-thrombotic 
agents before arrival at the PCI centre. However, more evidence is necessary to demonstrate 
whether high dose (HD) clopidogrel (600 mg) administered in the ambulance is associated 
with improved initial patency of the infarct related vessel (IRV) and/or clinical outcome 
compared to in-hospital initiation of HD clopidogrel. 
 
METHODS  
From 2001 until 2009 all consecutive ST-Segment Elevation Myocardial Infarction (STEMI) 
patients who underwent pre-hospital diagnosis and therapy in the ambulance were 
prospectively included in our single-centre cohort study. We compared initial patency of the 
IRV and clinical outcome in patients treated from 2001 until June 2006 (in-hospital HD 
clopidogrel) with patients treated from July 2006 until 2009 (ambulance HD clopidogrel). 
 
RESULTS  
A total of 2475 patients with STEMI were registered; of these 1110 (44.8%) received in-
hospital HD clopidogrel and 1365 (55.2%) received ambulance HD clopidogrel. Ambulance HD 
clopidogrel was not independently associated with initial patency (TIMI-2/3-flow pre-PCI 
(odds ratio: 1.18, 95% confidence interval [CI] 0.96–1.44); however, it was associated with 
fewer recurrent myocardial infarctions at 30 days (hazard ratio [HR]: 0.45, 95% CI 0.22–
0.93) and at one year (HR: 0.45, 95% CI 0.25–0.80). No difference in TIMI 2/3 flow post-PCI, 
major bleeding, mortality, MACE – and the combination of mortality and recurrent myocardial 
infarction at 30-days and at one year was present between the two groups. 
 
CONCLUSION 
In conclusion, early in-ambulance as compared to in-hospital initiation of HD clopidogrel in 
STEMI patients did not improve initial patency of the IRV or clinical outcome, except for a 
reduction of recurrent myocardial infarction. Therefore, early administration of HD clopidogrel 
seems to have net clinical benefit for these patients. 
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 INTRODUCTION 
Early reperfusion is the primary goal of treatment for ST-Segment Elevation Myocardial 
Infarction (STEMI) patients. Primary percutaneous coronary intervention (PCI) is the 
recommended treatment for STEMI patients if it can be performed within 90 minutes (min) 
after first medical contact according to the American Heart Association/American College of 
Cardiology [1]. It is the preferred therapy according to the European Society of Cardiology if a 
primary PCI can be performed within 60 min or within 90 min if patients need to be 
transferred from a referral non-PCI centre to a PCI centre [2]. Furthermore, pre-treatment 
with anti-platelet and anti-thrombotic agents are important components of the medical 
treatment for these patients. Pre-hospital diagnosis in the ambulance with early 
administration of anti-platelet and anti-thrombotic agents before primary PCI gives the 
opportunity to start medical treatment directly after diagnosis [3-6]. Pre-treatment with a 
thienopyridine, like clopidogrel, on top of aspirin and heparin is common practice in many 
countries for STEMI patients undergoing primary PCI. However, more definitive evidence is 
necessary for this pre-treatment despite recommendation in the abovementioned guidelines 
[1-2]. Therefore, we have investigated in a large STEMI population whether high dose (HD) 
clopidogrel (600 mg) on top of aspirin and heparin administered in the ambulance (ambulance 
HD clopidogrel) is associated with improved initial patency of the infarct related vessel (IRV) 
and improved clinical outcome compared to in-hospital administration of HD clopidogrel (in-
hospital HD clopidogrel). 
 
MATERIALS AND METHODS 
Since the early nineties STEMI patients were referred to the Isala hospital Zwolle and were 
treated by primary PCI. To improve the logistics of STEMI patients, the pre-hospital triage 
project was initiated. This has gradually been implemented in the region, starting in 1998. 
During the project all consecutive STEMI patients who were transported to our PCI centre 
from 1998 until 2009, were included in our cohort study prospectively. Criteria for the 
diagnosis of STEMI were: 1) history of cardiac symptoms of at least 30 min in the last 12 
hours (h) or between 12 and 24 h if they had persistent symptoms with evidence of ongoing 
ischaemia prior to presentation at the PCI centre or referral non-PCI centre, 2) elevated levels 
of creatin kinase (CK) or CK-MB and 3) concurrent electrocardiogram changes: ST-segment 
elevation of >0.1 mV in at least two adjacent electrocardiogram leads [7]. Information on 
angiographic outcome and short- and long-term clinical outcome were registered. 
Patients were excluded if they were referred via a referral non-PCI centre, were walk-ins at 
the PCI centre, if the type of pre-hospital triage was unknown, were admitted after an out of 
hospital cardiac arrest (OHCA) or were included in the Ongoing Tirofiban in Myocardial 
Infarction (On-TIME) 1 or 2 trial [8-9]. 
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 Procedures 
The algorithm of pre-hospital triage has been described previously [10]. In brief: After 
patients dialled the emergency number, patients were triaged in the ambulance. If STEMI was 
suspected, an electrocardiogram was made by highly trained paramedics and a computerised 
algorithm revealed the diagnosis. If a diagnosis of STEMI was made, the ambulance went 
straight to the catheterisation laboratory of a PCI centre, bypassing the emergency 
departments of the referral non-PCI centre. All patients were treated with an intravenous 
bolus of 5,000 IU unfractionated heparin and 500 mg aspirin intravenously in the pre-hospital 
phase. From 2001 until June 2006 HD clopidogrel (600 mg orally) was administrated either 
upon arrival of the patient in the emergency room (ER), in the catheterisation room, during or 
after PCI. From July first 2006 onward all patients received HD clopidogrel on top of aspirin 
and heparin in the ambulance. The date of July first 2006 constitutes the dividing line, since 
at that moment the ambulance protocols were adapted: administration of HD clopidogrel was 
added to their protocols. All patients were treated with dual anti-platelet therapy for at least 
six months. In all patients in whom PCI was performed, the procedure was performed through 
femoral access. No patients received fibrinolytic therapy. The primary outcome of the study, 
initial patency defined as Thrombolysis in Myocardial Infarction (TIMI) 2/3 flow of the IRV, 
was recorded at initial angiography and was assessed by the executive cardiologist as 
previously reported [11]. The secondary outcomes of the study were TIMI 2/3 flow of the IRV 
post-PCI, major bleeding, recurrent myocardial infarction (MI), mortality, Major Adverse 
Cardiac Events (MACE) - and the combination of mortality and recurrent MI at 30 days and at 
one year. Major bleeding was defined and classified according to the TIMI criteria: intracranial 
bleeding or overt non-coronary artery bypass grafting (CABG)-related bleeding with a 
decrease in haemoglobin ≥5 g/dl (≥3.1 mmol/l) or a decrease in haematocrit ≥15% within 48 
h after admission [12]. We used the following definition for recurrent MI: recurrent symptoms 
and/or new electrocardiographic changes in association with re-elevation of CK of >3 times 
the upper normal limit. More than five times the upper limit of normal CK was required for the 
diagnosis of MI after CABG. MACE was defined as mortality, recurrent MI and/or target vessel 
revascularisation. 
 
Time intervals 
Three different time intervals were evaluated: 1) Diagnosis-to-balloon time was defined as 
the time from diagnosis (time diagnostic electrocardiogram) to balloon inflation, 2) Door-to-
balloon time was defined as the time from arrival PCI centre to balloon inflation and 3) Total 
ischaemic time was defined as the time from symptom onset to balloon inflation. 
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Figure 1. Study Flowchart 
In total 6350 patients were transferred to our PCI centre. After excluding several  
patient groups 2475 patients were included in our study. Of these 2475 patients,  
1110 patients received in-hospital HD clopidogrel and 1365 patients received HD  
clopidogrel in the ambulance.  
HD: High Dose, OHCA: Out-of-Hospital Cardiac Arrest, On-TIME: Ongoing  
Tirofiban In Myocardial Infarction Evaluation, STEMI: ST-Segment Elevation  
Myocardial Infarction.  
 
Statistical analysis 
Statistical analysis was performed with SPSS 20.0 (Chicago, IL, USA). Continuous data were 
expressed as mean ± standard deviation or median and interquartile range. Categorical data 
were presented as percentage. A Mann-Whitney U test was used for comparing continuous 
data and Pearson’s Chi-square test or Fisher’s exact test was used for categorical data. 
Multivariable analyses were performed to estimate the effect of ambulance HD clopidogrel 
compared to in-hospital HD clopidogrel on TIMI 2/3 flow pre-PCI, on TIMI 2/3 flow post-PCI, 
on major bleeding, on MACE, and on the combination of mortality and recurrent MI at 30-days 
and at one year. Cox proportional-hazards regression models were used to estimate hazard 
ratios (HR) of recurrent MI - and mortality at 30 days and at one year. We corrected for the 
following baseline characteristics in the abovementioned analyses if they were defined as 
confounders: age, gender, diabetes mellitus, smoking, hypercholesterolemia, hypertension, 
83
6
 previous CABG, previous PCI, previous MI, Killip class >1, TIMI risk score, glycoprotein 
(GP)IIb/IIIa blocker administered in the acute phase, bailout GPIIb/IIIa blocker, total after 
ischaemic time, multivessel disease, thrombus aspiration, anterior infarction and stent choice. 
A landmark survival analysis was performed with the landmark time point chosen at 30 days 
the acute MI. The survival curves were compared by Log Rank test. To assess whether 
administration with GPIIb/IIIa blockers might interfere with the relationship between the type 
of clopidogrel treatment (in-hospital HD clopidogrel or ambulance HD clopidogrel) and TIMI 
2/3 flow pre-PCI, interaction testing was performed. To assess whether administration with 
GPIIb/IIIa blockers (either in acute phase or as bail-out therapy) might interfere with the 
relationship between the type of clopidogrel treatment and recurrent MI at 30 days or at one 
year, interaction testing was performed. Furthermore, interaction testing was performed to 
assess whether the type of stent used (bare metal stent [BMS], drug-eluting stent [DES] or 
no stent implanted) might interfere with the relationship between the type of clopidogrel 
treatment and recurrent MI at 30 days or at one year. All described statistical tests were 
performed two-sided. In all statistical analyses p-values <0.05 were considered statistically 
significant. 
 
The study was conducted according to the principles of the Declaration of Helsinki, and the 
protocol was approved by the local institutional review board. No extramural funding was 
used to support this work. The authors are solely responsible for the design and conduct of 
this study, all study analyses and drafting and editing of the paper. 
 
RESULTS 
From 2001 until 2009, a total of 6350 patients were referred to the Isala hospital Zwolle with 
the intention to perform primary PCI. As shown in the patient flow chart in Figure 1, of these 
2475 patients were referred after pre-hospital triage in the ambulance. Of these 2475 
patients, a total of 1110 patients (44.8%) received inhospital HD clopidogrel and 1365 
patients (55.2%) received HD clopidogrel in the ambulance. Patients treated with ambulance 
HD clopidogrel had a lower prevalence of smoking, they more often had a previous PCI, they 
were more often treated with GPIIb/IIIa blockers in the acute phase and pre- and/or post-
PCI, they had shorter door-to-balloon times and in this patient group more often thrombus 
aspiration before PCI was performed (Table 1). Results on angiographic and clinical outcome 
are described in Table 2. Patients treated with ambulance HD clopidogrel more often had a 
TIMI 2/3 flow pre-PCI and - post-PCI and a lower incidence of recurrent MIs (Table 2). With a 
landmark survival analysis it was demonstrated that the difference in recurrent MIs between 
the groups could only be demonstrated in the first 30 days (Figure 2). No difference in major 
bleeding, mortality, MACE and the combination of mortality and recurrent MI at 30 days or at 
one year was demonstrated.  
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 Table 1. Baseline clinical and angiographic characteristics  
Characteristic In-hospital HD 
clopidogrel 
n=1110 
Ambulance HD 
clopidogrel 
n=1365 
P  
Age (mean ± SD) 63.2 ± 12.7 (n=1110) 64.1 ± 12.8 (n=1365)   0.130 
Male gender 796/1110 (71.7%) 1017/1365 (74.5%)   0.118 
Diabetes mellitus 132/1104 (12.0%) 157/1361 (11.5%)   0.747 
Smoking 475/1069 (44.4%) 539/1355 (39.8%)   0.021 
Hypercholesterolemia 229/1012 (22.6%) 279/1306 (21.4%)   0.465 
Hypertension 374/1085 (34.5%) 490/1359 (36.1%)   0.415 
Previous coronary artery bypass grafting 53/1109 (4.8%) 50/1362 (3.7%)   0.170 
Previous PCI 92/1108 (8.3%) 149/1360 (11.0%)   0.027 
Previous myocardial infarction 104/1108 (9.4%) 150/1358 (11.0%)   0.177 
Killip class > 1 81/1100 (7.4%) 99/1365 (7.3%)   0.916 
TIMI risk score (mean ± SD, median, 
IQR) 
3.1 ± 2.2, 3.0 (1.0-4.0) 
(n= 304) 
2.9 ± 2.2, 3.0 (1.0-4.0) (n= 
1347) 
  0.318 
GPIIb/IIIa blocker* 92/1110 (8.3%) 610/1365 (44.7%) <0.001 
Bail-out GPIIb/IIIa blocker 417/1110 (37.6%) 470/1365 (34.4%)   0.106 
GPIIb/IIIa blocker pre- and/or post-PCI 496/1110 (44.7%) 929/1365 (68.1%) <0.001 
Diagnosis-to-balloon time (median, IQR) - 99 (78.3-128) (n=960)   -  
Door-to-balloon time (median, IQR) 55.0 (37.0-80.0) (n=943) 48.0 (31.0-75.0) (n=1093) <0.001 
Total ischemic time (median, IQR) 200.0 (145.0-298.8) 
(n=952) 
191.0 (140.3-317.8) 
(n=1088) 
  0.683 
Multivessel disease 558/1083 (51.5%) 653/1331 (49.1%)   0.229 
Thrombus aspiration 2/276 (0.7%) 381/1348 (28.3%) <0.001 
Anterior myocardial infarction 452/1088 (41.5%) 574/1332 (43.1%)   0.443 
Stent use: 
- No stent 
- BMS 
- DES 
 
231/948 (24.4%) 
537/948 (56.6%) 
180/948 (19.0%) 
 
358/1295 (27.6%) 
688/1295 (53.1%) 
249/1295 (19.2%) 
  0.174 
 * administered in the acute phase.  
BMS: bare metal stent, DES: drug eluting stent, GP: glycoprotein, HD: High Dose, IQR: inter quartile range,  
PCI: Percutaneous Coronary Intervention, SD: standard deviation, TIMI: Thrombolysis In Myocardial Infarction 
 
 
After multivariable adjustment, ambulance HD clopidogrel was not associated with TIMI 2/3 
flow pre-PCI (odds ratio [OR]: 1.18, 95% confidence interval [CI] 0.96-1.44, TIMI 2/3 flow 
post-PCI, major bleeding mortality, MACE or the combination of mortality and recurrent MI at 
30 day or one year. However, ambulance HD clopidogrel treatment was independently 
associated with less recurrent MIs at 30 days (HR: 0.45, 95% CI 0.22-0.93) and at one year 
(HR: 0.45, 95% CI 0.25-0.80) as compared to in-hospital HD clopidogrel treatment.  
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 Table 2. Angiographic and clinical outcome 
Characteristic In-hospital HD 
clopidogrel 
n=1110 
Ambulance HD 
clopidogrel 
n=1365 
P 
Angiographic outcome    
TIMI 2/3 flow pre-PCI 301/1015 (29.7%) 427/1149 (37.2%) <0.001 
TIMI 2/3 flow post-PCI 976/1012 (96.4%) 1125/1149 (97.9%)   0.038 
    
Clinical outcome    
TIMI Major bleeding 16/1075 (1.5%) 11/1364 (0.8%)   0.110 
30-day    
Mortality 35/1096 (3.2%) 46/1345 (3.4%)   0.756 
MACE 58/1096 (5.3%) 68/1345 (5.1%)   0.793 
Recurrent myocardial infarction 25/1096 (2.3%) 13/1345 (1.0%)   0.009 
Mortality or recurrent myocardial 
infarction 
57/1096 (5.2%) 57/1345 (4.2%)   0.262 
1 year    
Mortality 60/1025 (5.9%) 79/1294 (6.1%)   0.800 
MACE 98/1025 (9.6%) 123/1294 (9.5%)   0.964 
Recurrent myocardial infarction 39/1025 (3.8%) 23/1294 (1.8%)   0.003 
Mortality or recurrent myocardial 
infarction 
96/1025 (9.4%) 100/1294 (7.7%)   0.159 
HD: High Dose, MACE: Major Adverse Cardiac Event, PCI: Percutaneous Coronary Intervention,  
TIMI: Thrombolysis In Myocardial Infarction. 
 
Results of subgroup analyses are demonstrated in Table 3. Patients treated with bail-out 
GPIIb/IIIa blockers and ambulance HD clopidogrel had a lower incidence of recurrent MIs at 
30 days and at one year compared to patients treated with in-hospital HD clopidogrel. There 
was no significant interaction effect between the type of clopidogrel treatment and 
administration of GPIIb/IIIa blockers in the acute phase on TIMI 2/3 flow pre-PCI (p=0.269).  
There was no significant interaction effect between the type of clopidogrel treatment and 
administration of GPIIb/IIIa blockers (either in acute phase or as bail-out therapy) on 
recurrent MI at 30 days (p=0.912) or at one year (p=0.260). There was also no interaction 
effect between the type of clopidogrel treatment and type of stent used (BMS, DES or no 
stent implanted) on recurrent MI at 30 days (p=0.492) or at one year (p=0.288). 
 
DISCUSSION 
The most important finding of this study is that pre-hospital addition of HD clopidogrel on top 
of aspirin and heparin in the ambulance in STEMI patients did not improve initial patency of 
the IRV nor clinical outcome, except for a reduction of recurrent MI, as compared to patients 
treated with in-hospital initiation of HD clopidogrel. Our results can be explained by the fact 
that the peak effect of HD clopidogrel is time dependent [13-16].
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* administered in the acute phase.  
GP: glycoprotein, HD: high dose, PCI: percutaneous coronary intervention, TIMI: Thrombolysis In  
Myocardial Infarction. 
 
 
 
Figure 2. Recurrent myocardial infarction free patients 
A landmark analysis of recurrent myocardial infarction free patients is performed for the patients treated with 
in-hospital HD clopidogrel (narrow black line) and treated with ambulance HD clopidogrel (black line). 
 
In this study the clopidogrel preloading time was not sufficient to reach its peak of action and 
hence a lack of difference in IRV patency is the consequence. The second reason is that 
STEMI patients have an impaired bioavailability of clopidogrel, which results in suboptimal 
platelet inhibition [17]. The significant lower incidence of recurrent MI in patients treated with 
ambulance HD clopidogrel could only be demonstrated in the first 30 days. This might be due 
Table 3. Subgroup analyses 
 In-hospital HD 
clopidogrel 
Ambulance HD 
clopidogrel 
P 
GPIIb/IIIa blocker* (n=702)    
TIMI 2/3 flow pre-PCI 27/80 (33.8%) 237/546 (43.4%)   0.102 
Recurrent myocardial infarction at 30 days 1/90 (1.1%)  10/599 (1.7%)   0.694 
Recurrent myocardial infarction at 1 year 1/83 (1.2%) 14/588 (2.4%)   0.497 
    
Bail-out GPIIb/IIIa blocker (n=887)    
Recurrent myocardial infarction at 30 days 15/411 (3.6%) 3/463 (0.6%)   0.002 
Recurrent myocardial infarction at 1 year 18/378 (4.8%) 8/442 (1.8%)   0.016 
    
Thrombus aspiration (n=383)    
Recurrent myocardial infarction at 30 days 0/2 3/373 (0.8%)   1.000 
Recurrent myocardial infarction at 1 year - 6/369 (1.6%)   -  
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 to suboptimal platelet inhibition during the first 6-12 h after PCI especially in patients treated 
with in-hospital HD clopidogrel. Patients treated with HD clopidogrel in the ambulance had a 
pre-loading time of approximately 100 min, since the surrogate time interval (time from 
diagnosis to balloon inflation) was 99 (78.3-128) min, whereas the timing of administration of 
clopidogrel in the period before July first 2006 was later and not strict: 20% of the patients 
received the loading dose in the catheterisation laboratory, although the majority of the 
patients were treated after PCI was performed, most often in the cardiac care department. 
This relatively late administration in the latter patients might have put them at increased risk 
of recurrent MI. Furthermore, we anticipate that early clopidogrel administration might have 
had a protective effect on acute stent thrombosis and therefore the incidence of recurrent MIs 
decreased with ambulance HD clopidogrel. However, stent thrombosis was not prospectively 
collected in our database, and therefore this explanation should be read with cautiousness. As 
demonstrated in other STEMI trials, ambulance HD clopidogrel was not associated with an 
increased bleeding risk in these patients [18-22]. In the ACCOAST trial, however, an increase 
in TIMI major bleeding was demonstrated in patients assigned to inhospital pretreatment with 
prasugrel compared to placebo [23]. There were several trials which support our results [20-
21, 24]. Dörler et al. demonstrated that pre-treatment with clopidogrel did not improve initial 
patency of the IRV and reduced the incidence of recurrent MIs. However, they also showed 
that clopidogrel pre-treatment led to a reduced in-hospital mortality and stroke, which was 
not demonstrated in our study [20]. In the randomised controlled trial of Zeymer et al. 
(n=337), they have demonstrated that pre-hospital clopidogrel did not improve initial TIMI 
2/3 flow pre-PCI and ST-resolution 1 h post-PCI. However, this study was stopped 
prematurely [21]. Ducci et al. demonstrated in their small randomised trial (n=168) also no 
difference between pre- (900 or 600 mg) versus in-hospital (300 mg) administration of 
clopidogrel on TIMI 2/3 flow pre-PCI [24]. There were also trials who did not support our 
results on the TIMI 2/3 flow pre-PCI [18, 25-26]. Fever et al. and Lev et al. showed that pre-
treatment with clopidogrel reduced a composite endpoint of recurrent acute coronary 
syndrome, congestive heart failure, stent thrombosis and 30-day mortality [18], improved 
initial TIMI flow and reduced the incidence of recurrent MI [26]. A shortcoming in these two 
trials is the small sample size, which underpowered the studies to assess the effect of 
clopidogrel pre-treatment on mortality. Vlaar et al. demonstrated that pre-treatment with 
clopidogrel improved TIMI 2/3 flow pre-PCI and decreased mortality as well as the composite 
endpoint (mortality and MI). It is of importance to note that in the analysis of Vlaar et al. 
studies with different trial designs, pharmacologic therapies and PCI strategies during and 
after PCI were included [25]. In the large observational study of Koul et al. they 
demonstrated that clopidogrel treatment prior to arrival at the cathlab was associated with a 
reduction in the combined risk of mortality or MI as well as mortality alone in STEMI patients 
undergoing pPCI. However, they did not demonstrate a significant reduction in MI at one 
year, since after propensity scoring or multivariable analysis on top of propensity scoring the 
significant reduction in MI disappeared. Although, they stated that the general tendency in 
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 almost all trials is a reduction in MI with pre-treatment of clopidogrel. Unfortunately, the 
effect on initial patency was not examined. Furthermore, the clopidogrel loading dose was not 
specified to 300 or 600 mg and it was unknown whether all patients in the control group 
received clopidogrel in-hospital [22]. To improve initial patency of the IRV and clinical 
outcome in STEMI patients undergoing primary PCI, the results of pre-treatment with the 
GPIIb/IIIa blocker tirofiban, on top of aspirin, heparin and clopidogrel have been 
demonstrated [27]. The effect of tirofiban was time-dependent, whereas the time-dependent 
effect on initial patency was not found in the control group pre-treated with HD clopidogrel 
only [28]. As expected in our study, the difference in recurrent MI was not demonstrated in 
the patients who were treated with a GPIIb/IIIA blocker in the acute phase. Therefore, 
administration of a GPIIb/IIIa blocker seems to have a protective effect on recurrent MI. 
Recently, several trials have been initiated to assess the efficacy of pre-treatment in the 
ambulance with new agents, like ticagrelor (ATLANTIC trial, EudraCT number: 2011-000214-
19), which are characterised with an earlier peak of effects. However, it remains speculative 
whether the administration of an oral as compared to an intravenous agent is equally effective 
in patients with acute MI. Therefore, it might be very interesting to investigate the pre-
treatment effect of the intravenous agent cangrelor in the near future, because of its fast-
acting and rapidly reversible parenteral onset [29]. 
 
Limitations 
The exact time of administration of the HD clopidogrel was not collected prospectively, so it is 
impossible to assess the real loading dose-to-balloon time. This limitation is the consequence 
of the fact that our analyses are retrospective analyses from a prospective data registry. 
Since the project was not randomised and was dispersed over several years, consequently the 
risk of unknown confounders exists. The lack of randomisation might have led to selection 
bias. We decided that it was not appropriate to correct for selection bias by performing a 
propensity score matching procedure while concealed sources of bias ambush and therefore 
could lead to overestimation of the examined effect. The only known concealed source of bias 
in our study is the moment of admission at the PCI centre. The patients in this study were 
classified into the group ambulance HD clopidogrel or in-hospital HD clopidogrel based on the 
year and month of admission: on July first 2006 there was a protocol adaptation in the 
ambulances and from that time patients were treated with ambulance HD clopidogrel. 
Moreover, there are some confounders that were not present in the first years of the study. 
For example several study patients were pre-treated with GPIIb/IIIa blockers before primary 
PCI which occurred for the first time in 2005. Therefore, propensity score matching does not 
seems to be appropriate. The protocol adaptation in the ambulances on July 1, 2006 with HD 
clopidogrel administration coincided with an increase in pre-treatment with GPIIb/IIIa 
blockers before primary PCI and an increase in initiation of thrombus aspiration. Therefore, 
our results could reflect these effects rather than demonstrating the effect of ambulance HD 
clopidogrel alone. Interaction testing was not applicable for the effect of thrombus aspiration, 
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 because of the very few numbers of patients treated with in-hospital HD clopidogrel. However, 
adjustment for both variables was taken into account in the regression models. Currently, 
clopidogrel is no longer the P2Y12 blocker of choice as peri-procedural pharmacotherapy 
according to the guidelines [1-2]. Ticagrelor (ATLANTIC trial) and prasugrel should be 
suggested first, before considering clopidogrel administration. We are aware of the fact that 
the ischaemic time and door-to-balloon time in our study are relatively short and that our 
results can not be applied to STEMI patients with long ischaemic and long door-to-balloon 
times. 
 
Conclusion 
Early in-ambulance as compared to in-hospital initiation of HD Clopidogrel in STEMI patients 
did not improve initial patency of the IRV or clinical outcome, except for a reduction of 
recurrent MI. Therefore, early administration of HD clopidogrel seems to have net clinical 
benefit for these patients, who were included in a prospective cohort study and in which 
GPIIb/IIIa blocker administration in the acute phase increased during the years. 
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 ABSTRACT 
 
PURPOSE 
Grade 3 ischemia (G3I: distortion of the terminal portion of the QRS complex) is a predictor of 
serious complications after acute myocardial infarction. However, less is known about which 
patients are more prone to present with G3I. 
 
METHODS 
Patients who were enrolled in the Ongoing Tirofiban In Myocardial infarction Evaluation trial 2 
were included. These patients were divided in 2 groups based on the enrolment 
electrocardiogram: grade 2 ischemia (G2I) or G3I. 
 
RESULTS 
Between June 2004 and November 2007, 1308 patients with interpretable electrocardiograms 
were enrolled. Grade 3 ischemia was found in 426 (32.6%) patients. Patients with G3I were 
older, more often male, more often had diabetes, had a Thrombolysis In Myocardial Infarction 
(TIMI) risk score of greater than 3, had 3 vessel disease, had an anterior infarction, more 
often presented in Killip class greater than 1, less often had a pre-procedural TIMI 3 flow, and 
less often had a myocardial blush grade 3 post-PCI. One hour post-PCI, residual ST deviation 
was higher in patients with G3I compared with patients with G2I. Furthermore, G3I was 
associated with more major cardiac events (including death, myocardial infarction, urgent 
target vessel revascularization). After multivariate adjustment, G3I was an independent 
predictor of failure of ST-segment resolution 1 hour post-PCI (odds ratio, 1.4; 95% confidence 
interval, 1.1-1.9) and 30-day mortality (odds ratio, 3.2; 95% confidence interval, 1.2-8.7). 
 
CONCLUSION 
Grade 3 ischemia was associated with high-risk patient criteria (older age, diabetes, TIMI risk 
score N3, Killip class N1, and anterior myocardial infarction) and represents a subgroup of 
high-risk patients who seems to be associated with poor myocardial reperfusion and worse 
outcome. 
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 INTRODUCTION 
Primary percutaneous coronary intervention (pPCI) is a highly effective therapy to reestablish 
myocardial flow in patients with an ST-segment elevation myocardial infarction (STEMI). After 
pPCI, Thrombolysis In Myocardial Infarction (TIMI) 3 flow can be achieved in 85% to 95% of 
the patients; however, the prognosis of STEMI patients is highly dependent on the restoration 
of adequate perfusion at the level of the microcirculation [1-2]. Beyond the infarct related 
artery flow, ST-segment resolution (STR) seems to be an even stronger marker to identify 
tissue reperfusion [3-6]. In STEMI, incomplete STR (b70%) or failure of STR after reperfusion 
therapy is associated with worse outcome [4-5, 7-9]. 
Because early risk stratification for STEMI patients is crucial, numerous investigators have 
determined Electrocardiographic parameters to predict successful reperfusion in STEMI 
patients at admission [10-15]. One of these parameters is distortion of the terminal portion of 
the QRS complex (grade 3 ischemia [G3I]) described by Sclarovsky et al [16] and Birnbaum 
et al. [13]. This parameter has been identified as an independent predictor of failure of STR 
for STEMI patients who received reperfusion therapy and is associated with worse outcome 
[13, 16-21]. However, less is known about which patients are more prone to present with 
G3I, and therefore, we investigated this topic in a large population. 
 
METHODS 
Study population 
The Ongoing Tirofiban in Myocardial Evaluation (On-TIME) 2 trial was a prospective, 
multicenter, placebo-controlled, randomized clinical trial. The study consisted of 2 phases: (1) 
an open-label run-in phase and (2) a placebo-controlled double-blind phase. The rationale, 
study design, and primary results of the On-TIME 2 trial have been described previously [22-
23]. Patients with STEMI who underwent pPCI were included. Eligible patients were men and 
women aged between 21 and 85 years with symptoms of an acute myocardial infarction (MI) 
of more than 30 minutes but less than 24 hours and presented with ST-segment elevation 
(>0.1 mV in 2 adjacent Electrocardiographic [ECG] leads). Exclusion criteria were therapy-
resistant cardiogenic shock, renal dysfunction, persistent severe hypertension, 
contraindication to anticoagulation, increased bleeding risk, pregnancy or breastfeeding, life 
expectancy of less than 1 year, and left bundle-branch block.  
Written informed consent was obtained by an intensive care nurse in the ambulance or by a 
physician in a referral hospital. All local ethical committees involved approved the study 
protocol of the On-TIME 2 trial. 
 
Electrocardiographic analysis 
All interpretable and available ECGs of the On-TIME 2 patients were analyzed by 1 employee 
of an independent ECG core laboratory (Diagram BV, Zwolle, The Netherlands) who had no 
knowledge of the patients' angiographic or clinical outcome. In case of doubt, a second core-
laboratory employee reevaluated the ECG, and consensus was reached in all cases. ST-
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 segment elevation was measured at the J point in each lead, except aVR. STR was defined as 
the percent difference between the sum of ST-segment elevation at the diagnosis ECG and 
the sum of ST-segment elevation at the ECG pre-PCI (STR pre-PCI) or the ECG 1 hour post-
PCI (STR post-PCI). Complete STR was defined as 70% or greater resolution [24-25]. The 
sum of ST-segment deviation was measured 20 milliseconds after the end of the QRS complex 
compared to the isoelectric line with a caliper (diagnostic, pre-PCI, and 1 hour post-PCI). The 
grade of ischemia was analyzed at the diagnostic ECG and defined according to the ischemia 
grading system of Birnbaum et al [13]. Grade 3 ischemia was defined as (1) absence of an S 
wave below the TP-PR isoelectric line in 2 or more leads that usually have a terminal S 
configuration (leads V1-V3) or (2) ST J point amplitude of 50% or greater of the R-wave 
amplitude measured from the TP-PR baseline in 2 or more all other infarct-related leads 
(Figure 1).  
 
 
A 
 
B 
Figure 1.  
Diagnostic ECG of a patient with anterior ST-segment elevated myocardial infarction (STEMI) (A) and an 
inferior STEMI (B) showing grade 3 ischemia. There is ST-elevation in lead V1-V6 and there are no S waves in 
V2-V3 (A). There is ST-elevation in II, III and aVF and the ST J-point amplitude is ≥50% of the R wave 
amplitude in these leads (B).  
 
Patients meeting the ST-segment elevation criteria but not the aforementioned G3I criteria 
were defined as grade 2 ischemia (G2I) (Figure 2). Patients were excluded if the ST 
deviations were not fulfilling the study criteria. Furthermore, negative T waves were not 
considered for inclusion. 
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Figure 2.  
Diagnostic ECG of a patient with an anterior STEMI (A) and an inferior STEMI (B) showing grade 2 ischemia. 
There is ST-elevation in V2-V4, however S waves are present in V1-V3 (A). There is ST-elevation in lead II, III 
and aVF, however the J-point amplitude is below the 50% of the R wave amplitude (B). 
 
Angiographic analysis 
Coronary angiography and PCI were performed according to each institution's guidelines and 
standards. The angiograms were analyzed by an independent core laboratory (Diagram BV) 
without knowledge of the patient's electrographic or clinical outcome. The TIMI flow grade 
was assessed pre- and post-PCI, and myocardial blush grade (MBG) was assessed post-PCI as 
previously described [26-27]. Distal embolization and thrombus burden were defined as 
previously described [28-29]. 
 
Clinical end points 
The primary end point of the On-TIME2 trial was residual ST-segment deviation at 1 hour 
after PCI, as previously described [7,24]. The key secondary end point was major adverse 
cardiac events (death, recurrent MI, and target vessel revascularization [TVR]) at 30 days. 
Infarct size, which was one of the other end points, was calculated as the peak level of 
creatine kinase (CK) (peak CK) within 48 hours after admission [25]. A blinded independent 
clinical end-point committee adjudicated all clinical end points. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 17.0 (Chicago, Illinois). Continuous data were 
expressed as mean ± SD or median and interquartile range. Categorical data were presented 
as percentage. Analysis of variance was used for continuous data, and Pearson �2 test was 
used for the categorical data, respectively. For categorical data with a linear trend, a linear-
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 by-linear association test was used. We tested the associations between the variable “G3I” 
and other baseline characteristics using univariate logistic regression. The Mann-Whitney U 
test was used to calculate the time intervals between the G3I group and the G2I group 
because these were non-Gaussian distributed. To assess independent predictors of G3I, 
multivariate analysis was performed using a logistic regression analysis. In this analysis, 
univariate variables with P <0.10 were included. In all the statistical analyses, P ≤ 0.05 was 
considered statistically significant. 
 
RESULTS 
Between June 2004 and November 2007, 1385 patients were included in the On-TIME 2 trial. 
Twenty-nine patients (2.1%) were excluded because of incomplete or uninterpretable ECGs, 
and 48 patients (3.5%) were excluded because of ST deviations not fulfilling the study 
criteria. From the remaining 1308 patients, G3I was found in 426 patients (32.6%). Table 1 
summarizes the baseline characteristics of the patients. Patients with G3I were older, more 
often male, more often had diabetes, had a TIMI risk score of greater than 3, more often had 
triple vessel disease, had an anterior infarction, more often presented in Killip class greater 
than 1, less often had a preprocedural TIMI 3 flow, and less often had an MBG 3 post-PCI 
(Tables 1 and 2). Furthermore, these patients had a longer time from symptom onset (SO) to 
diagnosis and a prolonged ischemic time (Figure 3). 
 
 
Figure 3.  
The different time intervals are shown for patients with grade 2 ischemia and grade 3.  
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Table 1. Baseline characteristics 
Characteristic Total 
(N = 1308) 
Grade 2 ischemia 
(N = 882) 
Grade 3 ischemia 
(N = 426) 
P 
Age ± SD 61.69 ± 11.87 60.89 ± 11.81 63.33 ± 11.83 <0.001 
Male gender 996/1308 (76.1%) 657/882 (74.5%) 339/426 (79.6%)   0.043 
Hypertension 425/1304 (32.6%) 280/879 (31.9%) 145/425 (34.1%)   0.414 
Diabetes 144/1304 (11.0%) 84/879 (9.6%) 60/425 (14.1%)   0.014 
Smoking 612/1287 (47.6%) 420/868 (48.4%) 192/419 (45.8%)   0.388 
Hypercholesterolemia 322/1300 (24.8%) 209/877 (23.8%) 113/423 (26.7%)   0.259 
Family history 517/1276 (40.5%) 361/862 (41.9%) 156/414 (37.7%)   0.153 
Previous Angina 225/1301 (17.3%) 152/880 (17.3%) 73/421 (17.3%)   0.976 
Previous MI 109/1303 (8,4%) 67/879 (7.6%) 42/424 (9.9%)   0.163 
Previous PCI 100/1306 (7.7%) 64/881 (7.3%) 36/425 (8.5%)   0.442 
Previous CABG 24/1306 (1.8%) 19/881 (2.2%) 5/425 (1.2%)   0.217 
Previous CVA 20/1305 (1.5%) 15/880 (1.7%) 5/425 (1.2%)   0.467 
TIMI risk score >3 378/1290 (29.3%) 211/871 (24.2%) 167/419 (39.9%) <0.001 
Killip class >1 150/1280 (11.7%) 89/863 (10.3%) 61/417 (14.6%)   0.024 
Anterior MI 525/1228 (42.8%) 285/828 (34.4%) 240/400 (60%) <0.001 
Vessel disease     
One 659/1296 (50.8%) 462/872 (53.0%) 197/424 (46.5%)   0.028 
Two 354/1296 (27.3%) 228/872 (26.1%) 126/424 (29.7%)   0.176 
Three 219/1296 (16.9%) 131/872 (15.0%) 88/424 (20.8%)   0.010 
Left main 14/1296 (1.1%) 7/872 (0.8%) 7/424 (1.7%)   0.250 
IRV     
LAD 511/1235 (41.4%) 267/822 (32.5%) 244/413 (59.1%) <0.001 
RCA 559/1235 (45.3%) 430/822 (52.3%) 129/413 (31.2%) <0.001 
CX 149/1235 (12.1%) 115/822 (14.0%) 34/413 (8.2%)   0.003 
Graft 10/1235 (0.8%) 8/822 (1.0%) 2/413 (0.5%)   0.510 
LM 6/1235 (0.5%) 2/822 (0.2%) 4/413 (1.0%)   0.101 
Cum ST segment deviation*  14.65 ± 8.77 13.08 ± 7.08 17.90 ± 10.82 <0.001 
*Determined at the diagnostic ECG.  
CABG: coronary artery bypass grafting, CVA: cerebro vascular accident, Cum: cumulative, CX: circumflex, IRV: infarct  
related vessel, LAD: left anterior descending, LM: left main, MI: myocardial infarction, PCI: percutaneous  
coronary intervention, RCA: right coronary artery, SD: standard deviation, TIMI: thrombolysis in myocardial infarction.  
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Table 2. Angiographic, enzymatic, electrographic and clinical outcome 
Characteristic Grade 2 ischemia 
(N = 882) 
Grade 3 ischemia 
(N = 426) 
P  
Angiographic and enzymatic outcome    
TIMI 3 flow pre-PCI 187/803 (23.3%) 55/406 (13.5%) <0.001 
TIMI 3 flow post-PCI 690/760 (90.8%) 344/389 (88.4%)   0.208 
MBG 3 post-PCI 329/718 (45.8%) 145/368 (39.4%)   0.043 
Infarct size ± SD *(IU/l, N=1269) 1499 ± 1473  2295 ± 2059 <0.001 
Stent placement 680/767 (88.7%) 359/392 (91.6%)   0.122 
BMS 509/679 (75.0%) 271/359 (75.5%)   0.853 
DES  181/679 (26.7%) 92/359 (25.6%)   0.720 
Additional devices 118/845 (14.0%) 84/416 (20.2%)   0.005 
Rescue thrombosuction 81/845 (9.6%) 50/416 (12.0%)   0.183 
IABP 27/845 (3.2%) 31/416 (7.5%) <0.001 
Collaterals     0.245 
0 394/633 (62.2%) 231/340 (67.9%)  
1 165/633 (26.1%) 81/340 (23.8%)  
2 55/633 (8.7%) 20/340 (5.9%)  
3 19/633 (3.0%) 8/340 (2.4%)  
Distal embolisation pre-PCI 23/299 (7.7%) 5/109 (4.6%)   0.272 
Thrombus burden      0.003  
0 19/788 (2.4%) 6/395 (1.5%)  
1 49/788 (6.2%) 16/395 (4.1%)  
2 32/788 (4.1%) 12/395 (3.0%)  
3 139/788 (17.6%) 61/395 (15.4%)  
4 178/788 (22.6%) 79/395 (20.0%)  
5 371/788 (47.1%) 221/395 (55.9%)  
    
Electrographic outcome    
Com ST resolution pre-PCI 147/746 (19.7%) 34/338 (10.1%) <0.001 
Res ST deviation pre-PCI 10.55 ± 8.53 15.33 ± 10.35 <0.001 
Res ST deviation 1 hr post-PCI    
Mean (mm, N=1211) 3.60 ± 5.45  5.37 ± 5.71  <0.001 
0 mm 315/825 (38.2%) 79/386 (20.5%) <0.001 
1-3 mm 222/825 (26.9%) 91/386 (23.6%)  
4-6 mm 142/825 (17.2%) 97/386 (25.1%)  
>6 mm 146/825 (17.7%) 119/386 (30.8%)  
Res ST deviation >3 mm 1 hr post-PCI 288/825 (34.9%) 216/386 (56.0%) <0.001 
Com ST resolution 1 hr post-PCI 538/814 (66.1%) 214/381 (56.2%) <0.001 
    
Clinical outcome    
30-day    
Stroke 7/852 (0.8%) 2/408 (0.5%)   0.726 
MI  17/852 (2.0%) 10/408 (2.5%)   0.601 
Urgent TVR  28/852 (3.3%) 23/408 (5.6%)   0.048 
Death, MI, urgent TVR (MACE) 49/852 (5.8%) 43/408 (10.5%)   0.002 
 
Mortality  18/852 (2.1%) 21/408 (5.1%)   0.004 
1-year    
MI  21/846 (2.5%) 15/402 (3.7%)   0.218 
Mortality  31/846 (3.7%) 28/402 (7.0%)   0.010 
*peak CK 
BMS: bare metal stent, Com: complete, CK: creatine kinase, DES: drug eluting stent, IABP: intra aortic balloon pump,  
MACE: major adverse cardiac event, MBG: myocardial blush grade, MI: myocardial infarction, PCI: percutaneous  
coronary intervention, Res: residual, TIMI: thrombolysis in myocardial infarction, TVR: target vessel revascularization.  
 
Cumulative ST-segment deviation at the diagnostic ECG was higher for patients with G3I. One 
hour after PCI, residual ST-segment deviation and residual ST-segment deviation greater than 
3 mm post-PCI was higher in G3I patients. Furthermore, complete STR (STR pre-PCI and STR 
post-PCI) was lower in patients with G3I compared to G2I patients (Table 2). 
Moreover, G3I was associated with a larger infarct size, a higher 30-day mortality, a higher 1-
year mortality, more urgent TVRs at 30 days, and more major cardiac events (including 
death, MI, urgent TVR) (Table 2). After multivariate adjustment, G3I was an independent 
predictor of failure of STR post-PCI (odds ratio, 1.4; 95% confidence interval, 1.1-1.9) and 
30-day mortality (odds ratio, 3.2; 95% confidence interval, 1.2-8.7). 
 
DISCUSSION 
The primary finding of this study is that STEMI patients with a higher age, male sex, a TIMI 
risk score greater than 3, Killip class greater than 1, and anterior MI were more prone to 
present with G3I compared with G2I. Furthermore, G3I was identified as an independent 
predictor of failure of STR post-PCI and 30-day mortality. 
Careful risk assessment for each patient contributes to the decision making of physicians 
regarding therapeutic interventions, triage among alternative levels of hospital care, and 
allocation of clinical resources. Therefore, several electrocardiographic parameters have been 
identified as guiding management [10-15]. The parameter G3I has been demonstrated to be 
an independent predictor of failure of STR post-PCI and mortality for patients treated with 
thrombolytic therapy as well as for patients treated with pPCI [13, 16-21]. These results are 
consistent with our findings. Only baseline characteristics were included in the multivariate 
analyses because these data were present at the time of risk assessment. If we would have 
included angiographic parameters, the clinical predicting power would be reduced. 
To identify high-risk STEMI patients early after SO, we have demonstrated in the present 
study which characteristics and therefore which patients are more prone to present with G3I. 
Previous studies showed that a higher age [13, 20-21, 30], diabetes [13], and large infarct 
size were predictors of G3I [13, 17, 21, 30-31]. A TIMI risk score of greater than 3 has not 
been identified earlier as characteristics of G3I. In contrast to a previous study, more patients 
in our population with G3I were men [31]. However, we do not have a proper explanation for 
this significant difference. Some [13, 21] but not all [14, 17, 32-33], prior studies have shown 
a higher prevalence of Killip class greater than 1. We have demonstrated a higher prevalence 
of anterior STEMIs [17, 30] in contrast to other studies [13-14, 21, 32]. A possible 
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a higher prevalence of Killip class greater than 1. We have demonstrated a higher prevalence 
of anterior STEMIs [17, 30] in contrast to other studies [13-14, 21, 32]. A possible 
 
explanation for the higher prevalence might be that these anterior wall infarctions lead 
generally to larger infarct sizes that result in more tissue and microcirculatory damage and 
microvascular dysfunction [31]. Reduced TIMI 3 flow pre-PCI has also been described 
previously [31], whereas others showed reduced TIMI 3 flow post-PCI [19], no reflow post-
PCI [34, 35], or no association between G3I and TIMI flow at all [32]. Absence of MBG 3 post-
PCI has not prior been identified as consequence of G3I. Weaver et al [31] recently 
demonstrated no significant difference in MBG 3 post-PCI between G2I and G3I patients 
nevertheless, the sample size of their study was very small. Residual ST-segment deviation 
post-PCI was also higher in patients with G3I, which was also demonstrated by Birnbaum et al 
[21]. Furthermore, we found a prolonged time from SO to diagnosis and a prolonged ischemic 
time in patients with G3I in contrast to previous studies [13-14, 21]. 
The aforementioned data reveal that patients with G3I not only have less successful 
restoration of the blood flow in the epicardial coronary arteries but also have less successful 
reperfusion in the infarcted myocardium. Consequently, patients with G2I have a better 
protection of the myocardium and have less severe ischemia. The combination of 
aforementioned characteristics of patients with G3I might explain their worse outcome 
however, the reason why the extent and the grade of ischemia are related to worse outcome 
remains speculative.  
To improve treatment for patients with G3I, the simple electrographic measurement, available 
at the diagnostic ECG, should perhaps be implemented in routine practice (ie, implementation 
in protocols for STEMI patients). This might lead to a reduced diagnosis-to-door PCI time and 
more often to direct transport by ambulance to the catheterization laboratory of a PCI center, 
bypassing the emergency departments of non-PCI spoke centers. 
 
CONCLUSION 
Grade 3 ischemia, which may be diagnosed on the initial diagnostic ECG, was associated with 
high-risk patient criteria (older age, diabetes, TIMI risk score >3, Killip class >1, and anterior 
MI) and represents a subgroup of high-risk patients, which seems to be associated with poor 
myocardial reperfusion and worse outcome. The exact underlying mechanism explaining this 
type of distortion of the terminal portion of the QRS complex remains to be evaluated. 
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 ABSTRACT 
 
PURPOSE 
Few data exist on the predictive value of the extent of ST deviation in ST-elevation myocardial 
infarction (STEMI) patients. Therefore we have examined the predictive value of ST elevation 
and ST deviation in STEMI patients on 30-day and long term mortality. 
 
METHODS 
All STEMI patients with an interpretable diagnostic electrocardiogram (ECG), who were 
referred to the Isala hospital and were planned to undergo a primary percutaneous coronary 
intervention (pPCI) in the period 2001 until 2009, were prospectively registered in a cohort 
study. These patients were divided in tertiles based on the cumulative (cum) ST deviation and 
cum ST elevation, as assessed by an independent core-lab. 
 
RESULTS 
In total, 4513 patients were registered. 30-day mortality increased with cum ST deviation (0-
9 mm: 1.9%, >9-16 mm: 2.4%, >16mm: 3.9%, p=0.001), but not significant with cum ST 
elevation. Long term mortality (median follow up time of 7.1 years) increased with cum ST-
deviation (0-9 mm: 18.6%, >9-16 mm: 22.1%, >16 mm: 25.7%, p<0.001) and with cum 
ST-elevation (0-6 mm: 19.7%, >6-11 mm: 22.7%, >11 mm: 24.2%, p=0.070). After 
multivariable adjustment using Cox proportional Hazard models, cum ST deviation (T1: 
reference, T2: HR: 1.09 95% CI (0.67-1.77), T3: HR: 1.76 95% CI (1.14-2.73)) was 
independently associated with 30-day mortality. Both cum ST deviation (T1: reference, T2: 
HR:1.14 95% CI (0.98-1.34), T3: HR: 1.32 95% CI (1.13-1.53)) and ST elevation (T1: 
reference, T2: HR: 1.17 95% CI (1.00-1.38), T3: HR: 1.21 95% CI (1.04-1.42)) were 
independently associated with long term mortality. 
 
CONCLUSION 
Besides ST elevation, taking the extent of ST depression into account improves the predictive 
value of the diagnostic 12 lead ECG especially for 30-day mortality in STEMI patients who are 
planned to undergo pPCI. 
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 INTRODUCTION 
An electrocardiogram (ECG) represents a cheap and easy instrument to evaluate the risk of 
patients in the pre-hospital phase. Numerous specific markers on the ECG have been shown 
to predict clinical outcome for ST-segment elevation myocardial infarction (STEMI) patients, 
such as new left bundle branch block [1-2], the grade of ischemia [3-4], QRS width [1, 5], 
anterior myocardial infarction [1, 6] and ST elevation [1, 7-8]. Only few data are available on 
the predictive value of ST deviation (both ST elevation and depression) [1, 9-10]. Therefore, 
most treatment decisions in STEMI patients are not based upon the extent of this specific 
parameter. In fact, this marker might be very interesting, since acute transmural ischemia 
caused by occlusion of a major coronary artery produces an epicardial injury that can be 
detected as deviation of the ST-segment toward the involved myocardial region [11]. I.e. 
acute occlusion of the left anterior descending (LAD) or the right coronary artery (RCA) 
typically causes ST elevation while acute occlusion of the circumflex artery (CX) typically 
shows only ST depression in the 12 standard ECG leads [12]. Consequently, we hypothesized 
that it would be sufficient for the risk estimation of STEMI patients to also take ST depression 
into account besides ST elevation. The present study is conducted to investigate the 
predictive value of the extent of ST deviation as compared to the ST elevation in a large 
cohort of unselected STEMI patients. 
 
METHODS 
Patient population 
All STEMI patients with an available and interpretable diagnostic ECG, who were transported 
to the Isala hospital and were planned to undergo a primary percutaneous coronary 
intervention (pPCI) in the period 2001 until 2009, were included in a cohort study. Criteria for 
the diagnosis of STEMI were: (1) history of cardiac symptoms of at least 30 min in the last 12 
hours or between 12 and 24 hours if they had persistent symptoms with evidence of ongoing 
ischemia prior to presentation at the PCI centre or referral non-PCI centre, (2) elevated levels 
of Creatin Kinase or Creatin Kinase-MB and (3) concurrent ECG changes: ST elevation of 
>0.1mV in at least two adjacent ECG leads [13]. The municipal registration in the Netherlands 
was consulted for the mortality of all patients in this study. In case mortality could not be 
retrieved, patients were excluded from analysis. Patients with an uninterpretable diagnostic 
ECG, with an out of hospital cardiac arrest (OHCA) and patients of which the type of triage 
and transfer in the pre-hospital phase was unknown, were excluded. Infarct size was 
calculated as the peak level of CK (peak CK) within 24 hours after admission [14]. 
The included STEMI patients were divided in tertiles based on the cumulative (cum) ST 
deviation and based on cum ST elevation separately (T1, T2 and T3). 
 
pPCI procedure 
The staff of the catheterization laboratory of the PCI centre was pre-informed about the 
estimated time of arrival of the patient and was activated well before the arrival of the 
111
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 patient. In case the staff lived more than 30 minutes away from the PCI centre, they had to 
stay in the PCI centre while being on-call. All patients were treated pre-hospital with an 
intravenous bolus of 5000 IU of unfractionated heparin and 500 mg aspirin intravenously. 
During the study period the administration of clopidogrel on top of aspirin and heparin as pre-
hospital treatment was implemented from July first 2006. The administration of GPIIBIIIA 
blockers in the pre-hospital phase was left at the discretion of the referring physicians. The 
location of the acute vessel occlusion was determined in this study by the PCI operator. 
 
Electrocardiographic analysis 
All available and interpretable diagnostic ECGs were analyzed by an analyst of the 
independent ECG core-lab (Diagram BV) who had no knowledge of the patient’s angiographic 
or clinical outcome. In case of doubt, a second core-lab analyst re-evaluated the ECG and 
consensus was reached in all cases. ST elevation was measured at the J-point in each lead, 
except aVR. ST deviation (ST elevation plus ST depression in all leads, except aVR) was 
measured 20 ms after the end of the QRS complex compared to the isoelectric line with a 
calliper. 
 
Outcome measures 
The endpoints of this study are 30-day and long-term mortality. 
 
Time intervals 
Four different time intervals were evaluated: 1. Time from symptom onset (SO) to diagnosis 
(SO-Diagnosis). 2. Time from diagnosis (time diagnostic ECG) to arrival PCI centre 
(Diagnosis-Door PCI) 3. Time from arrival PCI centre to Balloon inflation (BI) (Door-to-
balloon: D2B) 4. Total ischemic time defined as the time from SO to BI. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 20.0 (Chicago, Illinois). Continuous data were 
expressed as mean ± SD or median and interquartile range. Categorical data were presented 
as percentage. A Kruskal-Wallis test was used for continuous data, since they were non-
Gaussian distributed. A Pearson’s Chi-square test was used for categorical data. The 
continuous variable infarct size was converted into a dichotomous variable by dividing the 
continuous variable in interquartile ranges and defining the interquartile range 0.75-1.00 as 
large enzymatic infarct size (75th percentile). 
Cox proportional Hazard models were constructed to estimate the effect of cum ST deviation 
and cum ST elevation separately on 30-day and on long-term mortality. At first we corrected 
for confounders of the pre-hospital phase and secondly we corrected additionally for CX as 
infarct related vessel (IRV) and three vessel disease (VD). 
Confounders included in the cum ST deviation model for 30-day mortality were age, killip 
class >1 and the tertiles of ST deviation. The same confounders were included for the model 
112 113
 for long term mortality, although previous myocardial infarction (MI) was included instead of 
age. Confounders included in the cum ST elevation model for 30-day mortality were smoking, 
hypercholesterolemia, previous MI, previous coronary artery bypass grafting (CABG) and killip 
class>1. For long term mortality the same confounders were included, nevertheless 
hypercholesterolemia was excluded. Confounders were only added to the Cox proportional 
Hazard models if they were considered as strong confounders. 
 
In all the statistical analyses p-values <0.05 were considered as statistical significant. The 
study was conducted according to the principles of the Declaration of Helsinki and the protocol 
was approved by the local institutional review board. No extramural funding was used to 
support this work. The authors are solely responsible for the design and conduct of this study, 
all study analyses and drafting and editing of the paper. 
 
RESULTS 
From 2001 until 2009, 6350 patients were referred to our hospital with the intention to 
perform pPCI. Of these, 773 patients (12.2%) had no (interpretable) diagnostic ECG, in 74 
patients (1.2%) mortality could not be retrieved, 405 patients (6.4%) had an OHCA, in 382 
(6.0%) the type of triage and transfer in the pre-hospital phase was unknown and 203 
patients (3.2%) were self referring patients. The remaining 4513 patients were divided in 
tertiles based on cum ST deviation (T1: 0-9 mm, T2: >9-16 mm and T3: >16 mm) and 
divided in tertiles based on cum ST elevation (T1: 0-6 mm, T2: >6-11 mm and T3: >11 mm) 
at the diagnostic ECG. The median follow-up time was 7.1 (interquartile range 4.7-9.4) years. 
 
Patient Characteristics 
The baseline characteristics are described in Table 1. Age and smoking differed among the 
tertiles of cum ST deviation. Cum ST deviation was associated with a lower prevalence of 
hypercholesterolemia, previous CABG, PCI and MI, with no VD and less often with the CX as 
infarct related vessel. Killip class >1 increased with cum ST deviation. 
The time intervals are described in Table 2. Time from diagnosis to arrival at the PCI center, 
D2B time and ischemic time decreased with cum ST deviation.  
The baseline characteristics and time intervals for cum ST elevation are described in Table 1 
and 2. 
 
Infarct size and clinical outcome 
Patients with high ST deviation (3rd tertile) more often had an occluded infarct related vessel 
(IRV), and a 2-fold larger infarct size. Both 30-day and long term mortality increased with 
cum ST deviation (Table 3 and Figure 1A).  
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 After multivariable adjustment using Cox proportional Hazard models for several pre-hospital 
confounders cum ST deviation was independently associated with 30-day mortality (T1: 
reference, T2: HR: 1.09 95% CI (0.67 to 1.77), T3: HR: 1.76 95% CI (1.14 to 2.73)) and 
with long term mortality (T1: reference, T2: HR: 1.14 95% CI (0.98 to 1.34), T3: HR: 1.32 
95% CI (1.13 to 1.53)). After additional correction for the CX as IRV and three VD the effect 
was more pronounced (see Table 4). The effects of cum ST elevation on infarct size and 
clinical outcome are depicted in Figure 1 B, Table 3 and 4. 
 
A  
B  
Figure 1. 
Cox regression curve of cum ST deviation (A) and cum ST elevation (B). 
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 Table 4. Cox regression analyses for ST deviation and ST elevation 
 ST deviation 
 30-day mortality HR (95% CI) Long term mortality HR (95% CI) 
Unadjusted effect T1: reference 
T2: HR 1.26 95% CI (0.78 to 2.05) 
T3: HR 2.06 95% CI (1.33 to 3.20) 
T1: reference 
T2: HR 1.16 95% CI (1.00 to 1.36) 
T3: HR 1.33 95% CI (1.15 to 1.55) 
Correction for confounders 
pre-hospital phase 
T1: reference 
T2: HR 1.09 95% CI (0.67 to 1.77) 
T3: HR 1.76 95% CI (1.14 to 2.73) 
T1: reference 
T2: HR 1.14 95% CI (0.98 to 1.34)  
T3: HR 1.32 95% CI (1.13 to 1.53) 
Correction for confounders 
pre and in-hospital phase  
(CX as IRV and 3VD) 
T1: reference 
T2: HR 1.16 95% CI (0.67 to 2.01) 
T3: HR 2.03 95% CI (1.24 to 3.33) 
T1: reference 
T2: HR 1.14 95% CI (0.97 to 1.35)  
T3: HR 1.32 95% CI (1.13 to 1.55) 
 ST elevation 
 30-day mortality HR (95% CI) Long term mortality HR (95% CI) 
Unadjusted effect T1: reference 
T2: HR 0.87 95% CI (0.54 to 1.40) 
T3: HR 1.39 95% CI (0.93 to 2.08) 
T1: reference 
T2: HR 1.10 95% CI (0.94 to 1.28) 
T3: HR 1.15 95% CI (0.99 to 1.33) 
Correction for confounders 
pre-hospital phase 
T1: reference 
T2: HR 0.95 95% CI (0.58 to 1.54) 
T3: HR 1.27 95% CI (0.82 to 1.96) 
T1: reference 
T2: HR 1.17 95% CI (1.00 to 1.38)  
T3: HR 1.21 95% CI (1.04 to 1.42) 
Correction for confounders 
pre and in-hospital phase  
(CX as IRV and 3VD)* 
T1: reference 
T2: HR 1.14 95% CI (0.68 to 1.94) 
T3: HR 1.44 95% CI (0.88 to 2.35) 
T1: reference 
T2: HR 1.18 95% CI (1.00 to 1.39)  
T3: HR 1.21 95% CI (1.03 to 1.42) 
*For long term mortality only additionally corrected for CX as IRV.  
CI: confidence interval, CX: circumflex, IRV: infarct related vessel, HR: hazard ratio, VD: vessel disease. 
 
DISCUSSION 
To our knowledge this is the first study to investigate the extent of cum ST deviation and cum 
ST elevation on the diagnostic ECG on 30-day and long term mortality in a large cohort of 
STEMI patients. The main finding is that both parameters are strongly associated with infarct 
size and independently predict long term mortality. However, taking the extent of ST segment 
depression into account, by looking at ST deviation and not merely ST elevation, seems to 
improve the predictive value. Furthermore, we have shown that after correction for CX as 
infarct related vessel, these effects were even more pronounced. 
Our results are in concordance with previous trials, although only several trials have 
investigated this issue. Hathaway et al. have shown in their large retrospective analysis of the 
GUSTO-1 trial, that ST deviation assessed on the initial ECG was a predictor of 30-day 
mortality, although no comparison was made between the predictive effect of ST deviation 
and ST elevation [1]. Furthermore, Martin et al. demonstrated in a cohort of STEMI and non-
STEMI patients that the consideration of both ST elevation and ST depression in the standard 
12 lead ECG recording significantly increases the sensitivity for the detection of STEMI with 
only a slight decrease in the specificity [9]. Although the predictive effect of ST deviation on 
mortality was not assessed, they validated the application of ST depression criteria with 
contrast-enhanced cardiac magnetic resonance imaging as the diagnostic gold standard. Knot 
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 et al. established in a cohort of STEMI and non-STEMI patients that similar strategies 
(emergency angiography with PCI whenever feasible) should be applied to both types of acute 
MI, since a MI with ST depression may represent a similar risk as a ST elevation acute MI 
[10].  
 
Characteristics of patients 
We found some contradiction in the risk of patients in the different tertiles of ST 
deviation/elevation. Patients in the lower tertiles had more baseline risk factors: they more 
often had hypercholesterolemia, a previous MI and underwent previous revascularization (PCI 
and CABG), whereas patients in the higher tertiles had more angiographic and clinical risk 
factors: they more often had an occluded IRV pre-PCI and more often presented with signs of 
heart failure. After multivariable adjustment, ST deviation independently predicted 30-day 
mortality, and both ST deviation and ST elevation independently predicted long term 
mortality. 
 
Time to treatment 
Overall, the time intervals decreased with cum ST deviation and cum ST elevation. This is of 
utmost importance, especially for patients of the highest tertiles, because with a higher extent 
of ST deviation or ST elevation outcome worsens. Highly trained paramedics and physicians in 
our area focus already on timely treatment for the high risk patients, although it could be 
decreased even more. In our study the difference in DTB time between the first and the third 
tertile was only 8 minutes. For patients with more than 15 mm ST deviation on the diagnostic 
ECG, every effort should be made to decrease time to reperfusion as short as possible. A time 
from Diagnosis-Door PCI of <40 minutes and a D2B time <30 minutes should be the standard 
goal for these patients. 
 
CX as IRV and three VD 
We expected on forehand an interaction effect between the CX as IRV and the tertiles of cum 
ST deviation on 30-day mortality and on long term mortality, since an acute occlusion of the 
CX typically produces only ST depression in the 12 standard ECG leads, however this effect 
could not be demonstrated. Nevertheless, after multivariable adjustment for CX as IRV and 
three VD, the effect of cum ST deviation and cum ST elevation on mortality (30-day and long 
term) was more pronounced. These results are in concordance with the results of Rasoul et al. 
They have demonstrated that patients with the CX as IRV, have a significantly worse clinical 
outcome [15]. 
Besides CX as IRV, three VD was also a strong predictor for 30-day and long term mortality. 
In general, patients affected with three VD have a larger infarction area at risk and therefore 
usually present with more ST depression and ST elevation, compared to patients with one or 
two vessel disease. 
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 Clinical outcome ST deviation versus ST elevation 
ST deviation is a predictor for 30-day and long term mortality, whereas ST elevation only 
predicts long term mortality. Despite the fact that the pathogenesis of concomitant ST 
depression in STEMI patients is still a matter of debate (reciprocal image of ST elevation in 
the infarct zone, additional ischemia beyond the infarct zone or more extensive infarction), 
several studies have demonstrated its prognostic impact in patient with ST elevation [16-18]. 
Therefore, it is plausible that beyond ST elevation also taking ST depression (ST deviation) in 
to account for the evaluation of myocardial perfusion gives more additional prognostic 
information in comparison with only ST elevation. 
 
Limitations 
At first, a major limitation of the current study is that up to 12.2% of the total population 
needed to be excluded because of missing or inadequate diagnostic ECGs. Secondly, since the 
project was not randomized and was dispersed over several years, consequently the risk of 
unknown confounders exists. Thirdly, the level of peak CK within 24 hrs was used as 
surrogate parameter for infarct size. Fourthly, to answer our research question it would 
probably be more suitable to develop prediction models, instead of association models. 
However the constructed prediction models could not be validated successfully in an external 
database, because we had no access to an external database which included ≥ 100 cases and 
non-cases [19]. 
 
Conclusion 
Besides ST elevation, taking the extent of ST depression into account improves the predictive 
value of the diagnostic 12 lead ECG especially for 30-day mortality in STEMI patients who are 
planned to undergo pPCI. 
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SUMMARY AND FUTURE PERSPECTIVES 
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 SUMMARY  
 
In PART I of the thesis, we have focussed on the pre-hospital diagnosis and triage in the 
ambulance (field triage) and pre-hospital treatment of ST-segment elevation myocardial 
infarction (STEMI) patients. The following items were investigated: type of transfer, 
residential distance, time delays and treatment strategies.  
 
In the introduction of the thesis (chapter 1), the current status of field triage and pre-
hospital treatment in STEMI patients was reviewed. An overview was constituted concerning 
pre-hospital infarct diagnosis and type of transfer, the organisation of networks, pre-hospital 
risk assessment and triage, time delays to treatment and pre-hospital treatment strategies 
including the thrombolytic therapy and antithrombotic agents. 
 
In chapter 2, referral of STEMI patients via field triage with direct transfer to a percutaneous 
coronary intervention (PCI) centre was compared to referral via non-PCI centres. It was 
demonstrated in a STEMI population of 5128 patients, that field triage resulted in a shorter 
ischemic time (OR for ischemic time <3 hours: 2.45, 95% CI 2.13-2.83), a smaller infarct size 
(OR for peak creatin kinase (CK) below the median for the total group: 1.19, 95% CI 1.04-
1.36) and a lower one year mortality (OR: 0.67, 95% CI 0.50-0.91). The benefits of field 
triage were more pronounced with longer distance from the patient’s residence to the nearest 
PCI centre. In addition, this type of triage increased the number of patients eligible to 
treatment according to the American and European guidelines. These results suggest that 
living at a longer distance from a PCI center may not negatively influence clinical outcomes 
when field triage with direct transfer to a PCI centre is available. 
 
In chapter 3 a similar comparison was made as in chapter 2 by systematic review. After 
literature search 14 randomized clinical trials (RCTs) were included in the systematic review, 
consisting of 20 treatment groups and 4474 participants. After multivariable frequency 
weighted logistic regression analysis it was revealed that field triage with direct transfer to a 
PCI centre was associated with a marked lower incidence of 30 day mortality (OR:0.58, 95% 
CI 0.37-0.89). Therefore, field triage with direct ambulance transport to a PCI hospital should 
become the treatment of choice for STEMI patients.  
 
The results of the comparison made in chapter 2 interested and encouraged us to investigate 
the relation between residential distance and ischemic time in more detail. We therefore 
examined this relation in a large cohort of 4149 STEMI patients in chapter 4. It was revealed 
that a longer distance from a patient’s residence to a PCI centre was associated with an 
increase in ischemic time in patients referred via a non-PCI centre (OR=1.11 95% CI 1.01-
1.12 for >60-90km compared to 0-30km). This effect was not demonstrated at a shorter 
distance or in patients referred via field triage. It was concluded that referral via field triage 
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 did not lead to a significant increase in ischemic time, especially at long distances of up to 
90km.  
 
System delay is defined as the time from first contact with the health care system to initiation 
of reperfusion therapy. It is currently one of the most interesting and highlighted time delays 
to treatment, because it can be minimised by optimizing the system. Several years ago it was 
demonstrated that system delay was associated with a higher incidence of mortality [1]. 
Since we expected that this effect would be more apparent in patients at high risk for large 
infarctions, we have investigated the influence of system delay on mortality in anterior versus 
non-anterior STEMI patients representing high and lower risk patients respectively, in 
chapter 5. In total, 3041 patients were included in our study consisting of 1253 patients with 
an anterior MI and 1788 with a non-anterior MI. These patients were divided into quartiles of 
system delay: Q1 for lowest to Q4 for highest quartile. It was demonstrated that prolonged 
system delay was associated with a higher 30 day mortality (Q1: reference, Q2: HR 1.18, 
95% CI 0.46-3.00; Q3: HR 2.45, 95% CI 1.07-5.63; Q4: HR 2.25, 95% CI 0.97-5.25) and 
long term mortality (Q1: reference, Q2: HR 1.09, 95% CI 0.71-1.68; Q3: HR 1.68, 95% CI 
1.13-2.49; Q4: HR 1.55, 95% CI 1.03-2.33) in patients with an anterior MI. This effect was 
not shown in patients with a non-anterior MI. Therefore, we believe it is of the greatest 
importance to minimize system delay in STEMI patients who present with an anterior MI. 
 
Besides the type of referral, residential distance to a PCI centre and time intervals, pre-
hospital treatment strategies are also very important for the outcome of STEMI patients. 
Pretreatment with a thienopyridine, like clopidogrel, on top of aspirin and heparin (prior to 
PCI) was common practice in many countries for numerous years [2]. Currently, the new 
P2Y12 receptor inhibitors ticagrelor and prasugrel, are preferred over clopidogrel [3]. 
However, at the time this study was performed, clopidogrel was the treatment of choice. 
Since definitive evidence for pre-hospital treatment strategies was lacking, this topic was 
investigated in chapter 6. In a STEMI population of 2475 patients we demonstrated that pre-
hospital treatment with a high dose (HD) of clopidogrel  (600 mg) did not improve pre-PCI 
thrombolysis in myocardial infarction (TIMI) flow compared to in-hospital treatment (OR: 
1.18, 95% CI 0.96-1.44) after multivariable adjustment for relevant confounders. 
Nevertheless, pretreatment with clopidogrel was associated with a lower incidence of 
recurrent myocardial infarctions (MIs) at 30 days (HR: 0.45, 95% CI 0.22-0.93) and at one 
year (HR: 0.45, 95% CI 0.25-0.80). No difference in post PCI TIMI 2/3 flow, major bleeding, 
mortality, major adverse cardiac events (MACE) and the combination of mortality and 
recurrent MI at 30 days and at one year was present between the two groups. Therefore, 
early administration of HD clopidogrel appears to have net clinical benefit.  
 
 
124 125
 In PART II of the thesis predictors for STEMI patients at risk were investigated. We examined 
two determinants depicted on the diagnostic ECG that were associated with high risk of 30 
day mortality and/or failure of ST-segment resolution (STR) one hour post PCI in STEMI 
patients.  
 
The study described in chapter 7 was a sub study of the On-TIME 2 trial and was performed 
to explore which baseline characteristic of STEMI patients are associated with grade 3 
ischemia (G3I: distortion of the terminal portion of the QRS complex). It was demonstrated 
that patients with G3I were older, more often male, more often had diabetes, a TIMI risk 
score >3, an anterior infarction, three vessel disease, more often presented in Killip class >1, 
pre-procedural TIMI flow <3 and myocardial blush grade <3 post PCI. Furthermore, it was 
demonstrated that at one hour post PCI, residual ST deviation was higher in patients with G3I 
compared to patients with grade 2 ischemia and G3I was associated with a higher incidence of 
MACE. After multivariable adjustment, G3I was an independent predictor of failure of STR at 
one hour post PCI (OR: 1.4, 95% CI 1.1-1.9) and 30 day mortality (OR: 3.2; 95% CI 1.2-
8.7). 
 
Since many years ST elevation is an important parameter for treatment decisions in STEMI 
patients. A disadvantage of this parameter is that not all acute occlusions lead to ST 
elevation. I.e. in patients with an acute occlusion of the circum flex artery ST depressions are 
frequently present. Only few data exist about the extent of ST elevation and ST deviation as 
predictors of mortality in STEMI patients. Therefore, we investigated this topic in a large 
population of STEMI patients (n=4513) (chapter 8). It was demonstrated that the extent of 
cum ST deviation predicts 30-day mortality (T1: reference, T2: OR: 1.09 95% CI (0.67-1.77), 
T3: OR 1.76 95% CI (1.14-2.73)). The extent of both cum ST elevation (T1: reference, T2: 
OR: 1.17 95% CI (1.00-1.38), T3: OR: 1.21 95% CI (1.04-1.42)) and cum ST deviation (T1: 
reference, T2: OR: 1.14 95% CI (0.98-1.34), T3: OR: 1.32 95% CI (1.13-1.53)) predicts long 
term mortality (median: 7.1 years, IQR: 4.7-9.4). Therefore, besides ST elevation also taking 
the extent of ST depression into account improves the predictive value of the diagnostic 12 
lead ECG especially for 30-day mortality in STEMI patients who are planned to undergo pPCI. 
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 FUTURE PERSPECTIVES 
 
Over the past two decennia much effort has been made concerning the treatment of STEMI 
patients, although there is still room and necessity for improvement. An increasing interest 
has been shown in the pre-hospital diagnosis, triage, and treatment of STEMI patients.  
 
Field triage 
Several trials, including our cohort study and systematic review, have demonstrated that field 
triage with direct transfer to a PCI centre improves clinical outcomes for STEMI patients [4-5]. 
Therefore, more effort should be put into direct transfer worldwide. Consequently, it is 
important to make patients and general practitioners aware of the benefits of this type of 
transfer compared to self-referring and referring via general practitioners or via a non-PCI 
center. Furthermore, it is essential for the diagnosis of STEMI patients that electrocardiogram 
(ECG) equipment with a computerized electrographic algorithm or telecommunication 
(referred to as ‘telemedicine’) is available to reach an accurate diagnosis. In fact, failure of 
the pre-hospital diagnosis is one of the main reasons why STEMI patients are initially 
transferred to a non-PCI centre [6]. Therefore, adequate training of (para)medics is of utmost 
importance. In addition, it would be interesting to explore further reasons why patients are 
not transferred to a PCI centre directly and if possible develop solutions to these issues.  
 
Determinants timely access PCI centre 
The distance that a patient has to cover to reach a PCI centre is a potential determinant of 
outcome that has not been studied in the same detail as the effect of different time intervals 
[1, 7-13]. As demonstrated in two of our studies, at long residential distances referral via field 
triage did not lead to an increase in time to treatment compared to short distance. In fact, the 
benefits of field triage were more pronounced at long residential distances [4, 12]. Therefore, 
it might be interesting to incorporate residential or ‘true’ travel distance together with type of 
transfer, beyond time intervals, in the decision making of timely reperfusion therapy for 
STEMI patients. Controversially, expansion of PCI centres may play less a role in the overall 
improvement of timely treatment of STEMI patients, since Concannon et al. and Horwitz et al. 
both demonstrated that opening new PCI centres did not help patients to gain timely access 
to PCI [14-15]. In addition, our results demonstrated that residential distance is not 
significantly associated with total ischemic time if patients are transferred via field triage [12]. 
The number, availability and expertise of the interventional cardiologists also plays an 
important role in providing timely access to PCI as well as the expertise of ambulance 
personnel. In the future more attention is needed on changes in PCI capacity and on the 
effects of these changes on outcome measures as well as on the selection of high-risk 
patients for transfer.  
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 Time delays to treatment 
Aiming for short time intervals will remain a topic of great importance, especially in high risk 
patients [16]. Since the time from symptom onset to call for help and diagnosis is usually 
very long, it is likely that there is much health gain to be expected in shortening this time 
delay. Therefore, more attention should be given to awareness of the symptoms of MI by the 
national and regional health care programs. Furthermore, as described earlier, direct transfer 
to a PCI center after field triage is an important predictor of timely treatment and improves 
clinical outcome, and should therefore preferably be implemented worldwide if the landscape, 
traffic and weather conditions allow this type of transfer.  
 
Pre-hospital treatment 
There is a clear lack of evidence into the efficacy of pre-hospital treatment, while there is 
much to gain by improving this treatment. For example for the COX-1 inhibitor, aspirin, the 
pre-hospital treatment effect has not been studied individually and for clopidogrel several 
cohort studies, one systematic review and only one underpowered RCT have been performed 
[17-26]. It is highly unlikely that new RCTs investigating pre-hospital treatment of clopidogrel 
will be designed. However, for the novel antithrombotic agents this might be the case. 
Currently two studies have investigated the pre-hospital administration of bivalirudin and 
ticagrelor. The first results of the Euromax trial demonstrated that pre-hospital administration 
of the direct thrombin inhibitor, bivalirudin, reduced major bleeding compared with both 
patients treated with heparin only plus bailout glycoprotein IIb/IIIa inhibitors (GPI), but 
increased acute stent thrombosis. The latter was probably the result of the combination of 
delayed bioavailability and rapid clearance [27]. The Atlantic trial investigated pre- versus in-
hospital treatment with the reversible ADP receptor antagonist ticagrelor, which together with 
prasugrel is the preferred P2Y12 receptor inhibitor according to the current guidelines [2]. It 
was demonstrated that prehospital administration of ticagrelor in patients with acute STEMI 
appeared to be safe, but did not improve pre-PCI coronary reperfusion [28]. Despite the 
evidence for GPI from the On-TIME 2 trial [29], the most recent European guideline and the 
American guideline concluded that the administration of pre-hospital GPI is of uncertain 
benefit [30].  
Given the importance of timely treatment of MI, preferably started in the pre-hospital phase, 
it would be desirable to explore the possibility of pre-hospital treatment with the newer 
antithrombotic agents. Furthermore, it has to be kept in mind that reduction of bleeding is of 
equal importance as reduction of ischemic events as well as that interindividual differences in 
the response to the agents are present in STEMI patients. Treatment strategies will likely 
become more tailored to the individual patient, considering the interindividual variability in 
response to antithrombotic agents and the patient’s risk of bleeding.  
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 ECG parameters 
Finally, risk assessment in the acute phase is critical to facilitate optimal treatment and 
appropriate intensity of monitoring. The ECG is a cheap and easy instrument to evaluate this 
risk, and several specific markers on the ECG predict clinical outcome of STEMI patients. More 
effort should be put into use of the ECG and specifically into several markers on the ECG, like 
G3I and ST deviation beyond ST elevation [31-32]. These markers might be implemented in 
routine practice besides the current parameters, by implementation in algorithms of the ECG 
equipment for risk assessment of STEMI patients and in the training of (para)medics. 
Furthermore, more studies should be performed to evaluate whether telemedicine can further 
improve the pre-hospital diagnosis in STEMI patients. 
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 In DEEL I van dit proefschrift hebben we gefocust op de pre-hospitale diagnose en triage in 
de ambulance (veld triage) en op de pre-hospitale behandeling van ST-segment elevatie 
myocard infarct (STEMI) patiënten. De volgende onderwerpen werden onderzocht: type 
transport, woonafstand, tijdsintervallen en behandelstrategieën.  
 
De introductie van dit proefschrift (hoofdstuk 1) is een review over de huidige status van 
veld triage en de pre-hospitale behandeling van STEMI patiënten. Er is een overzicht gegeven 
van de pre-hospitale infarct diagnose en het type transport, de organisatie van netwerken, de 
pre-hospitale risicostratificatie en triage, de tijdsintervallen tot behandeling en de pre-
hospitale behandelstrategieën inclusief trombolytica en trombocytenaggregatieremmers.  
 
In hoofdstuk 2 werd verwijzing via veld triage met direct transport naar een percutaan 
coronair interventie (PCI) centrum vergeleken met verwijzing via een non-PCI centrum in 
STEMI patiënten. We hebben aangetoond in een STEMI populatie van 5128 patiënten, dat 
veld triage resulteert in een kortere ischemische tijd (odds ratio (OR) voor ischemische tijd 
<3 uur: 2.45, 95% BI 2.13-2.83), een kleinere infarctgrootte (OR voor piek creatine kinase 
(CK) minder dan de mediaan van de totale groep: 1.19, 95% BI 1.04-1.36) en een lagere 
mortaliteit op één jaar (OR: 0.67, 95% BI 0.50-0.91). De voordelen van veld triage werden 
duidelijker zichtbaar bij een langere woonafstand gemeten van patiënten hun huis tot het PCI 
centrum. Daarnaast hebben we aangetoond dat veld triage leidt tot een hoger aantal 
patiënten dat wordt behandeld volgens de Amerikaanse en Europese richtlijnen. De resultaten 
suggereren dat het wonen op een grote afstand van een PCI centrum niet per se een 
negatieve invloed heeft op klinische uitkomsten als veld triage met direct transport naar een 
PCI centrum voorhanden is.  
 
In hoofdstuk 3 is een overeenkomende vergelijking uitgevoerd als in hoofdstuk 2. Er is 
echter gebruik gemaakt van een ander studie design, namelijk van een systematische review. 
Na literatuuronderzoek hebben we 14 gerandomiseerde klinische trials (RCT’s) geïncludeerd in 
de systematische review, bestaande uit 20 behandelgroepen en 4474 patiënten. Na het 
uitvoeren van een multivariabele frequentie gewogen logistische regressie analyse is gebleken 
dat veld triage met direct transport naar een PCI centrum was geassocieerd met een lagere 
30-dagen mortaliteit (OR:0.58, 95% BI 0.37-0.89). Daarom zijn wij van mening dat veld 
triage met direct ambulance transport naar een PCI centrum het type transport zou moeten 
zijn waarmee STEMI patiënten naar een PCI centrum worden vervoerd.  
 
De resultaten van de vergelijking die gemaakt is in hoofdstuk 2 hebben ons aangemoedigd 
om de relatie tussen woonafstand en ischemische tijd verder te onderzoeken (hoofdstuk 4). 
We hebben aangetoond in een cohort van 4149 STEMI patiënten dat een langere woonafstand 
was geassocieerd met een toename in ischemische tijd in patiënten die werden verwezen via 
een non-PCI centrum (OR=1.11 95% BI 1.01-1.12 voor >60-90km in vergelijking met 0-
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 30km). Dit effect kon niet aangetoond worden bij een kortere afstand of in patiënten die 
werden verwezen via veld triage. Onze conclusie was dat verwijzing via veld triage niet tot 
een significante langere ischemische tijd leidt, met name op grote afstanden (tot 90 km).  
 
Het zogenaamde ‘system delay’ is gedefinieerd als de tijd tussen het eerste medische contact 
en het moment van reperfusie. Het is momenteel één van de tijdsintervallen die de meeste 
belangstelling krijgt, omdat het kan worden geminimaliseerd door optimalisatie van het 
systeem. Een aantal jaren geleden is aangetoond dat ‘system delay‘ was geassocieerd met 
een hogere mortaliteit [1]. Aangezien we verwachten dat dit effect duidelijker naar voren 
komt bij patiënten met een hoog risico voor grote MI’s, hebben we de invloed van system 
delay op mortaliteit onderzocht in hoofdstuk 5 in STEMI patiënten met een voorwandinfarct 
versus geen voorwand infarct respectievelijk hoog versus laag risico patiënten.  
In totaal werden er 3041 patiënten geïncludeerd in onze studie, waarvan 1253 met een 
anterior MI en 1788 patiënten met een non-anterior MI. Deze patiënten hebben we 
vervolgens ingedeeld in kwartielen (K1: laagste kwartiel, K4: hoogste kwartiel). We hebben 
aangetoond dat een lange system delay geassocieerd was met een hogere 30-dagen 
mortaliteit (K1: referentie; K2: HR 1.18, 95% BI 0.46-3.00; K3: HR 2.45, 95% BI 1.07-5.63; 
K4: HR 2.25, 95% BI 0.97-5.25) en langere termijn mortaliteit (K1: referentie, K2: HR 1.09, 
95% BI 0.71-1.68; K3: HR 1.68, 95% BI 1.13-2.49; K4: HR 1.55, 95% BI 1.03-2.33) in 
patiënten met anterior MI. Dit effect werd niet aangetoond bij patiënten met een non-anterior 
MI. Daarom zijn wij van mening dat het van groot belang is om system delay te 
minimaliseren in STEMI patiënten met een anterior MI.  
 
Naast het type van verwijzing, de woonafstand naar een PCI centrum en tijdsintervallen, zijn 
de pre-hospitale behandelstrategieën ook erg belangrijk voor de uitkomsten van STEMI 
patiënten. De behandeling vóór aankomst in het PCI centrum (voorbehandeling) met een 
thiënopyridine, zoals clopidogrel, bovenop aspirine en heparine (toegediend vóór de PCI) was 
een gebruikelijke behandeling in vele landen voor meerdere jaren [2]. Momenteel hebben de 
nieuwe P2Y12 receptor inhibitors, ticagrelor en prasugrel, de voorkeur in plaats van 
clopidogrel [3]. Echter, op het moment dat dit onderzoek werd uitgevoerd, was clopidogrel de 
eerste keuze van P2Y12 receptor inhibitors volgens de richtlijnen. Aangezien sluitend bewijs 
voor de voorbehandeling ontbrak, hebben we dit onderwerp onderzocht in hoofdstuk 6. In 
een STEMI populatie van 2475 patiënten hebben we aangetoond dat voorbehandeling met 
een hoge dosis (HD) clopidogrel (600 mg) niet leidde tot een verbeterde thrombolysis in 
myocardial infarction (TIMI) flow pre-PCI in vergelijking met in-hospitale behandeling met 
clopidogrel (geen voorbehandeling) (OR: 1.18, 95% BI 0.96-1.44). Echter, voorbehandeling 
met clopidogrel was geassocieerd met een lagere incidentie van myocardinfarcten (MI’s) op 
30 dagen (HR: 0.45, 95% BI 0.22-0.93) en op één jaar (HR: 0.45, 95% BI 0.25-0.80). Er was 
geen verschil in TIMI 2/3 flow post PCI, grote bloedingen, mortaliteit, major adverse cardiac 
events (MACE) en de combinatie van mortaliteit en MI’s op 30 dagen en op één jaar tussen de 
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 twee groepen. Concluderend blijkt voorbehandeling met HD clopidogrel te leiden tot een netto 
klinisch voordeel. 
 
 
In DEEL II van dit proefschrift werden voorspellers onderzocht van hoog risico patiënten. We 
hebben twee determinanten van het diagnose ECG onderzocht die geassocieerd waren met 
een hoog risico op 30-dagen mortaliteit en/of het ontbreken van ST-segment resolutie (STR) 
1 uur na PCI.  
 
Het onderzoek beschreven in hoofdstuk 7 is een substudie van de On-TIME 2. We hebben 
onderzocht welke baselinekarakteristieken van STEMI patiënten geassocieerd zijn met graad 3 
ischemie (G3I: vervorming van het laatste gedeelte van het QRS complex). We hebben 
aangetoond dat patiënten met G3I zich presenteerden met de volgende kenmerken: hoge 
leeftijd, mannelijk geslacht, diabetes, TIMI risico >3, anterior MI, drievatslijden, Killip klasse 
>1, pre-procedurele TIMI flow <3 en een myocardial blush grade <3 na PCI. Daarnaast 
hebben we aangetoond dat 1 uur na PCI residuele ST deviatie hoger was in patiënten met G3I 
in vergelijking met patiënten met graad 2 ischemie en dat G3I geassocieerd was met een 
hogere incidentie van MACE. Na multivariabele correctie was G3I een onafhankelijke 
voorspeller voor 30-dagen mortaliteit (OR: 3.2; 95% BI 1.2-8.7) en voor het ontbreken van 
STR 1 uur na PCI (OR: 1.4, 95% BI 1.1-1.9). 
 
Sinds vele jaren is ST elevatie een belangrijke parameter voor beslissingen aangaande de 
behandeling van STEMI patiënten. Een nadeel van deze parameter is dat niet alle acute 
occlusies leiden tot ST elevatie. Een acute occlusie van de circum flex is namelijk vaak 
geassocieerd met ST depressies. Tot nu toe is er weinig onderzoek gedaan naar de grootte 
van cumulatieve ST elevatie en cumulatieve ST deviatie als voorspellers voor mortaliteit in 
STEMI patiënten. Daarom hebben we hier onderzoek naar gedaan in een STEMI populatie van 
4513 patiënten (hoofdstuk 8). We hebben aangetoond dat de grootte van cumulatieve ST 
deviatie 30-dagen mortaliteit voorspelt (T1: referentie, T2: OR: 1.09 95% BI (0.67-1.77), T3: 
OR 1.76 95% BI (1.14-2.73)). De grootte van zowel cumulatieve ST elevatie (T1: referentie, 
T2: OR: 1.17 95% BI (1.00-1.38), T3: OR: 1.21 95% BI (1.04-1.42)) als cumulatieve ST 
deviatie (T1: referentie, T2: OR: 1.14 95% BI (0.98-1.34), T3: OR: 1.32 95% BI (1.13-1.53)) 
voorspelt lange termijn sterfte (mediaan: 7.1 jaar, IQR: 4.7-9.4). Daarom is het van belang 
dat naast cumulatieve ST elevatie ook de grootte van cumulatieve ST deviatie wordt 
meegenomen, zodat de voorspellende waarde van het 12 afleidingen ECG vergroot wordt met 
name voor 30-dagen mortaliteit in STEMI patiënten die gepland zijn om een primaire PCI te 
ondergaan.  
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De Maatschap Cardiologie van de Isala Zwolle ben ik zeer erkentelijk voor het vertrouwen dat 
ik de afgelopen jaren heb gekregen. Het is uniek dat er in een perifeer topklinisch ziekenhuis 
een database van infarctpatiënten is opgezet waarbij de eerste patiënten als sinds 1990 zijn 
geregistreerd. Deze zogenaamde BAMI database is dan ook een belangrijke bron voor 
wetenschappelijk onderzoek van vele promovendi. Dank dat ik gebruik het mogen maken van 
deze database. 
 
Dr. Dambrink wil ik ook hartelijk bedanken voor de feedback die ik iedere keer heb gekregen 
op de manuscripten. Ik heb dit erg op prijs gesteld.  
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 De prettige samenwerking met de cardiologen en arts-assistenten van de Isala tijdens mijn 
werkzaamheden als researchmedewerker en ten tijde van mijn werk als projectcoördinator, 
heeft mij veel gebracht. Vincent, Dirk, Rik, Balázs, José en Amber bedankt in het bijzonder.  
 
Zonder de goede samenwerking met de ambulancediensten; RAV IJsselland, UMCG 
ambulancezorg en Witte Kruis ambulancedienst had ik een aantal vraagstukken niet kunnen 
beantwoorden. Dank Rudolf, Frank en Hans voor de prettige samenwerking! 
 
Toos en Yvonne. Bij jullie kon ik altijd terecht voor het regelen van afspraken, 
handtekeningen en wat nog niet meer. Dank voor het feit dat jullie altijd klaar staan. 
 
Vera, als jij er ook niet was. Dank voor het corrigeren en submitten van mijn abstracts en 
artikelen. Wat is het af en toe een precisiewerkje en wat ben ik blij dat jij dit voor mij doet! 
 
Beste Tom. Al ken ik je niet persoonlijk, erg bedankt voor het opzoeken van alle artikelen die 
ik nodig had! Ik heb dit zeer op prijs gesteld. 
 
Wouter, jij hoort ook zeker in het rijtje thuis. Jouw kennis en enthousiasme om mensen te 
motiveren en het uiterste uit mensen te halen heeft mij zo geïnspireerd dat ik zelf 
promotieonderzoek ben gaan doen. Deze eigenschappen zullen je zeker nog ver brengen, 
daar ben ik van overtuigd. Dank voor de leerzame en mooie tijd gehad tijdens mijn stage in 
het St. Antonius. Jij bent mijn kruiwagen geweest, zoals je het zelf altijd noemde, en daar 
ben ik je tot op de dag van vandaag nog altijd zeer dankbaar voor! 
 
Alle collega’s van Diagram. Menigeen heeft mij wel gevraagd “Sonja wat doe jij nou precies 
voor onderzoek naast je werk?” Hopelijk hebben jullie na het lezen van de Nederlandse 
samenvatting een aardig beeld waar ik de afgelopen jaren aan heb gewerkt. Dank voor alle 
hulp die in heb ontvangen, de interesse en de support! Ik heb het erg gewaardeerd. Een 
aantal collega’s wil ik in het bijzonder bedanken: 
 
Dick en Jaap, dank voor het meedenken, het vertrouwen en jullie support! Evelien heel erg 
bedankt voor alle hulp bij de statistische analyses. Dankzij jouw tip ben ik de masteropleiding 
Epidemiologie gaan volgen. Mijn dank is zeer groot. Petra, dank voor jou specialistische 
expertise bij de gecompliceerde vraagstukken. Ik heb hier erg veel van opgestoken. Als 
laatste dank aan mijn kamergenootjes (Anita, Ilse, Monique, Sina, Angelique en Leonie) voor 
een luisterend oor. 
 
Mijn paranimfen, Anouk Wienke en Heleen Bouman.  
Lieve Anouk, dank voor het zijn van een vriendin en collega. Ik vind het heel erg fijn dat jij zij 
aan zij staat bij de verdediging van dit proefschrift. Alle goeds voor de toekomst toegewenst.  
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 Lieve Heleen, jaren geleden is de vriendschap begonnen als ‘vampieren’ op de afdeling 
cardiologie en klinische chemie in het St. Antonius. Wat hebben we er een mooie tijd gehad! 
Dank dat ik een aantal jaren geleden aan jouw zij mocht staan en het is een eer dat je nu aan 
mijn zij staat! Succes met de glansrijke carrière die jou te wachten staat en veel geluk 
toegewenst! 
 
De Theunies (Grietje, Dirtzen, Marije, Nynke, Tjitske, Jacobien, Maayke, Marinke en Lotte). 
Vriendinnen sinds de middelbare school. Wat hebben we toch allemaal iets moois bereikt! Van 
pubers tot carrièrevrouwen en van single ladies naar moeders. Dank voor de support en 
gezelligheid. Dat de dates nog maar jaren mogen voortduren. 
 
Ook dank voor de support en gezelligheid van mijn vriendinnen Jannie en Veronica. Jannie we 
kennen elkaar als sinds de basisschool en zijn nog altijd goede vriendinnen. Ik heb er het 
volste vertrouwen in dat onze vriendschap nog vele jaren blijft bestaan. Veronica, wij zaten 
jaren in hetzelfde schuitje. Een aantal jaar geleden ben jij al gepromoveerd. Nu heb je een 
mooie baan bij Nestlé. Succes met een glansrijke carrière, die je naar verwachting tegemoet 
zult gaan! 
 
Mijn heit en mem. Lieve heit en mem dank voor jullie begrip, vertrouwen en support de 
afgelopen jaren in de keuzes die ik heb gemaakt.  
 
Lieve broertjes, dank voor jullie interesse en support. Alle goeds toegewenst voor de 
toekomst. 
 
Mijn schoonouders, Paul en Wietske. Ook jullie dank voor het vertrouwen en luisterend oor. 
Paul, dank voor alle hulp bij de totstandkoming van het boekje. 
 
Inge & Nico en de kids. Dank voor jullie interesse en support! 
 
Allerliefste Iwan en Sven. Jullie ben ik wel het allermeeste dank verschuldigd. Ik heb 
behoorlijk wat ‘quality time’ ingeleverd de afgelopen jaren, om dit proefschrift tot stand te 
laten komen. Ik zal vanaf nu meer tijd hebben om samen te kunnen genieten van het 
gezinsleven. Ik ha jim leaf! 
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